{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:13:29Z","timestamp":1794345209215,"version":"4.9.0"},"reference-count":468,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since the proposal of Paul Ehrlich\u2019s magic bullet concept over 100 years ago, tremendous advances have occurred in targeted therapy. From the initial selective antibody, antitoxin to targeted drug delivery that emerged in the past decades, more precise therapeutic efficacy is realized in specific pathological sites of clinical diseases. As a highly pyknotic mineralized tissue with lessened blood flow, bone is characterized by a complex remodeling and homeostatic regulation mechanism, which makes drug therapy for skeletal diseases more challenging than other tissues. Bone-targeted therapy has been considered a promising therapeutic approach for handling such drawbacks. With the deepening understanding of bone biology, improvements in some established bone-targeted drugs and novel therapeutic targets for drugs and deliveries have emerged on the horizon. In this review, we provide a panoramic summary of recent advances in therapeutic strategies based on bone targeting. We highlight targeting strategies based on bone structure and remodeling biology. For bone-targeted therapeutic agents, in addition to improvements of the classic denosumab, romosozumab, and PTH1R ligands, potential regulation of the remodeling process targeting other key membrane expressions, cellular crosstalk, and gene expression, of all bone cells has been exploited. For bone-targeted drug delivery, different delivery strategies targeting bone matrix, bone marrow, and specific bone cells are summarized with a comparison between different targeting ligands. Ultimately, this review will summarize recent advances in the clinical translation of bone-targeted therapies and provide a perspective on the challenges for the application of bone-targeted therapy in the clinic and future trends in this area.<\/jats:p>","DOI":"10.1038\/s41392-023-01467-8","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T10:02:37Z","timestamp":1684317757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Targeting strategies for bone diseases: signaling pathways and clinical studies"],"prefix":"10.1038","volume":"8","author":[{"given":"Hao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-2803","authenticated-orcid":false,"given":"Dechun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"1467_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nature10763","volume":"481","author":"G Karsenty","year":"2012","unstructured":"Karsenty, G. & Ferron, M. The contribution of bone to whole-organism physiology. Nature 481, 314\u2013320 (2012).","journal-title":"Nature"},{"key":"1467_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1593","volume":"13","author":"M Zaidi","year":"2007","unstructured":"Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791\u2013801 (2007).","journal-title":"Nat. Med."},{"key":"1467_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt, K. & Ullrich, A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473\u2013480 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1467_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-pathol-011110-130203","volume":"6","author":"X Feng","year":"2011","unstructured":"Feng, X. & McDonald, J. M. Disorders of bone remodeling. Annu. Rev. Pathol. 6, 121\u2013145 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"1467_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid, I. R. & Billington, E. O. Drug therapy for osteoporosis in older adults. Lancet Lond. Engl. 399, 1080\u20131092 (2022).","journal-title":"Lancet Lond. Engl."},{"key":"1467_CR6","doi-asserted-by":"publisher","first-page":"101623","DOI":"10.1016\/j.beem.2022.101623","volume":"36","author":"NM Appelman-Dijkstra","year":"2022","unstructured":"Appelman-Dijkstra, N. M., Oei, H. L. D. W., Vlug, A. G. & Winter, E. M. The effect of osteoporosis treatment on bone mass. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101623 (2022).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"1467_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/485047a","volume":"485","author":"M Zaidi","year":"2012","unstructured":"Zaidi, M. & Iqbal, J. Translational medicine: double protection for weakened bones. Nature 485, 47\u201348 (2012).","journal-title":"Nature"},{"key":"1467_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan, A. A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 30, 3\u201323 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR9","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-021-01587-x","volume":"81","author":"LPB Elbers","year":"2021","unstructured":"Elbers, L. P. B., Raterman, H. G. & Lems, W. F. Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: a narrative review. Drugs 81, 1645\u20131655 (2021).","journal-title":"Drugs"},{"key":"1467_CR10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","volume":"106","author":"BL Langdahl","year":"2021","unstructured":"Langdahl, B. L., Hofbauer, L. C. & Forfar, J. C. Cardiovascular safety and sclerostin inhibition. J. Clin. Endocrinol. Metab. 106, 1845\u20131853 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1467_CR11","doi-asserted-by":"crossref","unstructured":"Barbehenn, E. K., Lurie, P. & Wolfe, S. M. Osteosarcoma risk in rats using PTH 1-34. Trends Endocrinol. Metab. TEM 12, 383 (2001).","DOI":"10.1016\/S1043-2760(01)00489-1"},{"key":"1467_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-022-00219-8","volume":"10","author":"S Bolamperti","year":"2022","unstructured":"Bolamperti, S., Villa, I. & Rubinacci, A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Res. 10, 1\u201319 (2022).","journal-title":"Bone Res"},{"key":"1467_CR13","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/brv.12302","volume":"92","author":"JD Currey","year":"2017","unstructured":"Currey, J. D., Dean, M. N. & Shahar, R. Revisiting the links between bone remodelling and osteocytes: insights from across phyla. Biol. Rev. Camb. Philos. Soc. 92, 1702\u20131719 (2017).","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"1467_CR14","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/nm.3668","volume":"20","author":"H Xie","year":"2014","unstructured":"Xie, H. et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med. 20, 1270\u20131278 (2014).","journal-title":"Nat. Med."},{"key":"1467_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80536-2","volume":"11","author":"L Sapra","year":"2021","unstructured":"Sapra, L. et al. Lactobacillus rhamnosus attenuates bone loss and maintains bone health by skewing Treg-Th17 cell balance in Ovx mice. Sci. Rep. 11, 1807 (2021).","journal-title":"Sci. Rep."},{"key":"1467_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3181\/00379727-186-42590A","volume":"186","author":"WM Pierce","year":"1987","unstructured":"Pierce, W. M. & Waite, L. C. Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro. Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. N. Y. N. 186, 96\u2013102 (1987).","journal-title":"Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. N. Y. N."},{"key":"1467_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.addr.2004.12.011","volume":"57","author":"D Wang","year":"2005","unstructured":"Wang, D., Miller, S. C., Kope\u010dkov\u00e1, P. & Kope\u010dek, J. Bone-targeting macromolecular therapeutics. Adv. Drug Deliv. Rev. 57, 1049\u20131076 (2005).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1467_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jconrel.2017.11.009","volume":"269","author":"SG Rotman","year":"2018","unstructured":"Rotman, S. G. et al. Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. J. Control. Release 269, 88\u201399 (2018).","journal-title":"J. Control. Release"},{"key":"1467_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nm.3791","volume":"21","author":"C Liang","year":"2015","unstructured":"Liang, C. et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat. Med. 21, 288\u2013294 (2015).","journal-title":"Nat. Med."},{"key":"1467_CR20","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1016\/j.bioactmat.2021.02.014","volume":"6","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss. Bioact. Mater. 6, 2905\u20132913 (2021).","journal-title":"Bioact. Mater."},{"key":"1467_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.semcdb.2020.05.016","volume":"112","author":"K S\u00f8e","year":"2021","unstructured":"S\u00f8e, K., Delaisse, J.-M. & Borggaard, X. G. Osteoclast formation at the bone marrow\/bone surface interface: importance of structural elements, matrix, and intercellular communication. Semin. Cell Dev. Biol. 112, 8\u201315 (2021).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1467_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/nm.2448","volume":"17","author":"J Xiong","year":"2011","unstructured":"Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235\u20131241 (2011).","journal-title":"Nat. Med."},{"key":"1467_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","volume":"20","author":"LE Theill","year":"2002","unstructured":"Theill, L. E., Boyle, W. J. & Penninger, J. M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20, 795\u2013823 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"1467_CR24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20051150","volume":"202","author":"M Asagiri","year":"2005","unstructured":"Asagiri, M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261\u20131269 (2005).","journal-title":"J. Exp. Med."},{"key":"1467_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"3","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889\u2013901 (2002).","journal-title":"Dev. Cell"},{"key":"1467_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337\u2013342 (2003).","journal-title":"Nature"},{"key":"1467_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.2653","volume":"18","author":"K Maeda","year":"2012","unstructured":"Maeda, K. et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18, 405\u2013412 (2012).","journal-title":"Nat. Med."},{"key":"1467_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jb\/mvv124","volume":"159","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi, Y., Uehara, S., Udagawa, N. & Takahashi, N. Featured: regulation of bone metabolism by Wnt signals. J. Biochem. 159, 387 (2016).","journal-title":"J. Biochem."},{"key":"1467_CR29","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1172\/JCI45913","volume":"121","author":"AD Barrow","year":"2011","unstructured":"Barrow, A. D. et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J. Clin. Invest. 121, 3505\u20133516 (2011).","journal-title":"J. Clin. Invest."},{"key":"1467_CR30","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00018-016-2425-5","volume":"74","author":"CM Karner","year":"2017","unstructured":"Karner, C. M. & Long, F. Wnt signaling and cellular metabolism in osteoblasts. Cell. Mol. Life Sci. 74, 1649\u20131657 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"1467_CR31","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3389\/fimmu.2019.01663","volume":"10","author":"PPC Souza","year":"2019","unstructured":"Souza, P. P. C. & Lerner, U. H. Finding a toll on the route: the fate of osteoclast progenitors after Toll-like receptor activation. Front. Immunol. 10, 1663 (2019).","journal-title":"Front. Immunol."},{"key":"1467_CR32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nm.4076","volume":"22","author":"J Luo","year":"2016","unstructured":"Luo, J. et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med. 22, 539\u2013546 (2016).","journal-title":"Nat. Med."},{"key":"1467_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","volume":"473","author":"BF Boyce","year":"2008","unstructured":"Boyce, B. F. & Xing, L. Functions of RANKL\/RANK\/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473, 139\u2013146 (2008).","journal-title":"Arch. Biochem. Biophys."},{"key":"1467_CR34","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1242\/jcs.108.8.2729","volume":"108","author":"HK V\u00e4\u00e4n\u00e4nen","year":"1995","unstructured":"V\u00e4\u00e4n\u00e4nen, H. K. & Horton, M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J. Cell Sci. 108, 2729\u20132732 (1995).","journal-title":"J. Cell Sci."},{"key":"1467_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/0014-4827(88)90191-7","volume":"175","author":"IA Silver","year":"1988","unstructured":"Silver, I. A., Murrills, R. J. & Etherington, D. J. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp. Cell Res. 175, 266\u2013276 (1988).","journal-title":"Exp. Cell Res."},{"key":"1467_CR36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1126\/science.276.5310.266","volume":"276","author":"SA Nesbitt","year":"1997","unstructured":"Nesbitt, S. A. & Horton, M. A. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276, 266\u2013269 (1997).","journal-title":"Science"},{"key":"1467_CR37","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1517\/13543784.9.6.1281","volume":"9","author":"GD Hartman","year":"2000","unstructured":"Hartman, G. D. & Duggan, M. E. alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption. Expert Opin. Investig. Drugs 9, 1281\u20131291 (2000).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1467_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jbmr.5650070314","volume":"7","author":"MH Helfrich","year":"1992","unstructured":"Helfrich, M. H., Nesbitt, S. A., Dorey, E. L. & Horton, M. A. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J. Bone Miner. Res. 7, 335\u2013343 (1992).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR39","first-page":"4991","volume":"86","author":"KB Apparao","year":"2001","unstructured":"Apparao, K. B. et al. Osteopontin and its receptor alphavbeta(3) integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. J. Clin. Endocrinol. Metab. 86, 4991\u20135000 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1467_CR40","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1128\/MCB.00259-08","volume":"28","author":"H Epple","year":"2008","unstructured":"Epple, H. et al. Phospholipase Cgamma2 modulates integrin signaling in the osteoclast by affecting the localization and activation of Src kinase. Mol. Cell. Biol. 28, 3610\u20133622 (2008).","journal-title":"Mol. Cell. Biol."},{"key":"1467_CR41","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.2489","volume":"17","author":"T Negishi-Koga","year":"2011","unstructured":"Negishi-Koga, T. et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med. 17, 1473\u20131480 (2011).","journal-title":"Nat. Med."},{"key":"1467_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nature11000","volume":"485","author":"M Hayashi","year":"2012","unstructured":"Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69\u201374 (2012).","journal-title":"Nature"},{"key":"1467_CR43","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/cells9092073","volume":"9","author":"J-M Kim","year":"2020","unstructured":"Kim, J.-M., Lin, C., Stavre, Z., Greenblatt, M. B. & Shim, J.-H. Osteoblast-osteoclast communication and bone homeostasis. Cells 9, 2073 (2020).","journal-title":"Cells"},{"key":"1467_CR44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nm.1979","volume":"15","author":"Y Tang","year":"2009","unstructured":"Tang, Y. et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757\u2013765 (2009).","journal-title":"Nat. Med."},{"key":"1467_CR45","doi-asserted-by":"publisher","first-page":"93S","DOI":"10.1016\/8756-3282(95)00186-H","volume":"17","author":"JM Hayden","year":"1995","unstructured":"Hayden, J. M., Mohan, S. & Baylink, D. J. The insulin-like growth factor system and the coupling of formation to resorption. Bone 17, 93S\u201398S (1995).","journal-title":"Bone"},{"key":"1467_CR46","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1172\/JCI69493","volume":"123","author":"S Takeshita","year":"2013","unstructured":"Takeshita, S. et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J. Clin. Invest. 123, 3914\u20133924 (2013).","journal-title":"J. Clin. Invest."},{"key":"1467_CR47","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald, M. M. et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184, 1330\u20131347.e13 (2021).","journal-title":"Cell"},{"key":"1467_CR48","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/jbmr.3091","volume":"32","author":"NE Lassen","year":"2017","unstructured":"Lassen, N. E. et al. Coupling of bone resorption and formation in real time: new knowledge gained from human Haversian BMUs. J. Bone Miner. Res. 32, 1395\u20131405 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/15476286.2015.1017205","volume":"12","author":"C Zhao","year":"2015","unstructured":"Zhao, C. et al. miR-214 promotes osteoclastogenesis by targeting Pten\/PI3k\/Akt pathway. RNA Biol. 12, 343\u2013353 (2015).","journal-title":"RNA Biol."},{"key":"1467_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nm.3026","volume":"19","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. miR-214 targets ATF4 to inhibit bone formation. Nat. Med. 19, 93\u2013100 (2013).","journal-title":"Nat. Med."},{"key":"1467_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bone.2013.04.002","volume":"55","author":"K Shi","year":"2013","unstructured":"Shi, K. et al. MicroRNA-214 suppresses osteogenic differentiation of C2C12 myoblast cells by targeting Osterix. Bone 55, 487\u2013494 (2013).","journal-title":"Bone"},{"key":"1467_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10872","volume":"7","author":"D Li","year":"2016","unstructured":"Li, D. et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, 10872 (2016).","journal-title":"Nat. Commun."},{"key":"1467_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-018-0482-7","volume":"561","author":"Y Ikebuchi","year":"2018","unstructured":"Ikebuchi, Y. et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature 561, 195\u2013200 (2018).","journal-title":"Nature"},{"key":"1467_CR54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/d41586-018-05960-x","volume":"561","author":"M Zaidi","year":"2018","unstructured":"Zaidi, M. & Cardozo, C. P. Receptor becomes a ligand to control bone remodelling. Nature 561, 180\u2013181 (2018).","journal-title":"Nature"},{"key":"1467_CR55","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/jcb.20958","volume":"99","author":"T Komori","year":"2006","unstructured":"Komori, T. Regulation of osteoblast differentiation by transcription factors. J. Cell. Biochem. 99, 1233\u20131239 (2006).","journal-title":"J. Cell. Biochem."},{"key":"1467_CR56","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev-physiol-021119-034332","volume":"82","author":"AG Robling","year":"2020","unstructured":"Robling, A. G. & Bonewald, L. F. The osteocyte: new insights. Annu. Rev. Physiol. 82, 485\u2013506 (2020).","journal-title":"Annu. Rev. Physiol."},{"key":"1467_CR57","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.18632\/aging.101308","volume":"9","author":"LM Tiede-Lewis","year":"2017","unstructured":"Tiede-Lewis, L. M. et al. Degeneration of the osteocyte network in the C57BL\/6 mouse model of aging. Aging 9, 2190\u20132208 (2017).","journal-title":"Aging"},{"key":"1467_CR58","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2147\/DMSO.S239892","volume":"13","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. High glucose downregulates connexin 43 expression and its gap junction and hemichannel function in osteocyte-like MLO-Y4 cells through activation of the p38MAPK\/ERK signal pathway. Diabetes Metab. Syndr. Obes. Targets Ther. 13, 545\u2013557 (2020).","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"1467_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fphys.2014.00131","volume":"5","author":"LI Plotkin","year":"2014","unstructured":"Plotkin, L. I. Connexin 43 hemichannels and intracellular signaling in bone cells. Front. Physiol. 5, 131 (2014).","journal-title":"Front. Physiol."},{"key":"1467_CR60","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/acel.12586","volume":"16","author":"HM Davis","year":"2017","unstructured":"Davis, H. M. et al. Disruption of the Cx43\/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell 16, 551\u2013563 (2017).","journal-title":"Aging Cell"},{"key":"1467_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/srep44618","volume":"7","author":"TW Fowler","year":"2017","unstructured":"Fowler, T. W. et al. Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis. Sci. Rep. 7, 44618 (2017).","journal-title":"Sci. Rep."},{"key":"1467_CR62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41413-022-00198-w","volume":"10","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Targeting ferroptosis suppresses osteocyte glucolipotoxicity and alleviates diabetic osteoporosis. Bone Res. 10, 26 (2022).","journal-title":"Bone Res."},{"key":"1467_CR63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41413-018-0007-x","volume":"6","author":"AE Morrell","year":"2018","unstructured":"Morrell, A. E. et al. Mechanically induced Ca2+ oscillations in osteocytes release extracellular vesicles and enhance bone formation. Bone Res. 6, 6 (2018).","journal-title":"Bone Res."},{"key":"1467_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2106\/JBJS.G.01183","volume":"90","author":"P ten Dijke","year":"2008","unstructured":"ten Dijke, P., Krause, C., de Gorter, D. J. J., L\u00f6wik, C. W. G. M. & van Bezooijen, R. L. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Jt. Surg. Am. 90, 31\u201335 (2008).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"1467_CR65","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/bonekey.2015.126","volume":"4","author":"C Thouverey","year":"2015","unstructured":"Thouverey, C. & Caverzasio, J. Sclerostin inhibits osteoblast differentiation without affecting BMP2\/SMAD1\/5 or Wnt3a\/\u03b2-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro. Bonekey Rep. 4, 757 (2015).","journal-title":"Bonekey Rep."},{"key":"1467_CR66","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1073\/pnas.1019443108","volume":"108","author":"AR Keramati","year":"2011","unstructured":"Keramati, A. R. et al. Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proc. Natl Acad. Sci. USA 108, 1914\u20131918 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR67","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bone.2011.09.052","volume":"50","author":"W-Y Cheung","year":"2012","unstructured":"Cheung, W.-Y., Simmons, C. A. & You, L. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression. Bone 50, 104\u2013110 (2012).","journal-title":"Bone"},{"key":"1467_CR68","doi-asserted-by":"publisher","first-page":"17314","DOI":"10.1002\/jcp.28351","volume":"234","author":"F He","year":"2019","unstructured":"He, F. et al. Irradiation-induced osteocyte damage promotes HMGB1-mediated osteoclastogenesis in vitro. J. Cell. Physiol. 234, 17314\u201317325 (2019).","journal-title":"J. Cell. Physiol."},{"key":"1467_CR69","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.exger.2013.08.004","volume":"48","author":"C Kang","year":"2013","unstructured":"Kang, C., Chung, E., Diffee, G. & Ji, L. L. Exercise training attenuates aging-associated mitochondrial dysfunction in rat skeletal muscle: role of PGC-1\u03b1. Exp. Gerontol. 48, 1343\u20131350 (2013).","journal-title":"Exp. Gerontol."},{"key":"1467_CR70","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bone.2012.01.025","volume":"50","author":"OD Kennedy","year":"2012","unstructured":"Kennedy, O. D. et al. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone 50, 1115\u20131122 (2012).","journal-title":"Bone"},{"key":"1467_CR71","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1359\/jbmr.080207","volume":"23","author":"G Kogianni","year":"2008","unstructured":"Kogianni, G., Mann, V. & Noble, B. S. Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J. Bone Miner. Res. 23, 915\u2013927 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR72","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/jbmr.2740","volume":"31","author":"WY Cheung","year":"2016","unstructured":"Cheung, W. Y. et al. Pannexin-1 and P2X7-receptor are required for apoptotic osteocytes in fatigued bone to trigger RANKL production in neighboring bystander osteocytes. J. Bone Miner. Res. 31, 890\u2013899 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR73","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1172\/JCI134214","volume":"130","author":"D Andreev","year":"2020","unstructured":"Andreev, D. et al. Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin. J. Clin. Invest 130, 4811\u20134830 (2020).","journal-title":"J. Clin. Invest"},{"key":"1467_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03059-8","volume":"11","author":"J-Y Ru","year":"2020","unstructured":"Ru, J.-Y. & Wang, Y.-F. Osteocyte apoptosis: the roles and key molecular mechanisms in resorption-related bone diseases. Cell Death Dis. 11, 846 (2020).","journal-title":"Cell Death Dis."},{"key":"1467_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.abb.2014.05.003","volume":"561","author":"M Capulli","year":"2014","unstructured":"Capulli, M., Paone, R. & Rucci, N. Osteoblast and osteocyte: games without frontiers. Arch. Biochem. Biophys. 561, 3\u201312 (2014).","journal-title":"Arch. Biochem. Biophys."},{"key":"1467_CR76","doi-asserted-by":"crossref","unstructured":"Murshed, M., Harmey, D., Millan, J. I., McKee, M. D. & Karsenty, G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 19, 1093\u20131104 (2005).","DOI":"10.1101\/gad.1276205"},{"key":"1467_CR77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.abb.2008.03.027","volume":"473","author":"K Matsuo","year":"2008","unstructured":"Matsuo, K. & Irie, N. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 473, 201\u2013209 (2008).","journal-title":"Arch. Biochem. Biophys."},{"key":"1467_CR78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1359\/jbmr.061002","volume":"22","author":"RL van Bezooijen","year":"2007","unstructured":"van Bezooijen, R. L. et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res. 22, 19\u201328 (2007).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR79","doi-asserted-by":"publisher","first-page":"108052","DOI":"10.1016\/j.celrep.2020.108052","volume":"32","author":"KM Cawley","year":"2020","unstructured":"Cawley, K. M. et al. Local production of osteoprotegerin by osteoblasts suppresses bone resorption. Cell Rep. 32, 108052 (2020).","journal-title":"Cell Rep."},{"key":"1467_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28673-2","volume":"13","author":"M Uenaka","year":"2022","unstructured":"Uenaka, M. et al. Osteoblast-derived vesicles induce a switch from bone-formation to bone-resorption in vivo. Nat. Commun. 13, 1066 (2022).","journal-title":"Nat. Commun."},{"key":"1467_CR81","doi-asserted-by":"publisher","first-page":"24004","DOI":"10.1074\/jbc.M501080200","volume":"280","author":"JA Kennell","year":"2005","unstructured":"Kennell, J. A. & MacDougald, O. A. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. J. Biol. Chem. 280, 24004\u201324010 (2005).","journal-title":"J. Biol. Chem."},{"key":"1467_CR82","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","volume":"8","author":"TF Day","year":"2005","unstructured":"Day, T. F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt\/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8, 739\u2013750 (2005).","journal-title":"Dev. Cell"},{"key":"1467_CR83","doi-asserted-by":"publisher","first-page":"20764","DOI":"10.1073\/pnas.0805133106","volume":"105","author":"L Pederson","year":"2008","unstructured":"Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S. & Oursler, M. J. Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA 105, 20764\u201320769 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR84","first-page":"3231","volume":"133","author":"SJ Rodda","year":"2006","unstructured":"Rodda, S. J. & McMahon, A. P. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Dev. Camb. Engl. 133, 3231\u20133244 (2006).","journal-title":"Dev. Camb. Engl."},{"key":"1467_CR85","doi-asserted-by":"publisher","first-page":"13247","DOI":"10.1074\/jbc.M508324200","volume":"281","author":"J-S Nam","year":"2006","unstructured":"Nam, J.-S., Turcotte, T. J., Smith, P. F., Choi, S. & Yoon, J. K. Mouse cristin\/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression. J. Biol. Chem. 281, 13247\u201313257 (2006).","journal-title":"J. Biol. Chem."},{"key":"1467_CR86","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13287-021-02228-6","volume":"12","author":"Z-X Jin","year":"2021","unstructured":"Jin, Z.-X. et al. Osthole enhances the bone mass of senile osteoporosis and stimulates the expression of osteoprotegerin by activating \u03b2-catenin signaling. Stem Cell Res. Ther. 12, 154 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"1467_CR87","doi-asserted-by":"publisher","first-page":"102626","DOI":"10.1016\/j.ebiom.2020.102626","volume":"52","author":"G Shen","year":"2020","unstructured":"Shen, G. et al. Foxf1 knockdown promotes BMSC osteogenesis in part by activating the Wnt\/\u03b2-catenin signalling pathway and prevents ovariectomy-induced bone loss. EBioMedicine 52, 102626 (2020).","journal-title":"EBioMedicine"},{"key":"1467_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23374-8","volume":"12","author":"TW Fowler","year":"2021","unstructured":"Fowler, T. W. et al. Development of selective bispecific Wnt mimetics for bone loss and repair. Nat. Commun. 12, 3247 (2021).","journal-title":"Nat. Commun."},{"key":"1467_CR89","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0092-8674(01)00374-9","volume":"105","author":"R Dajani","year":"2001","unstructured":"Dajani, R. et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721\u2013732 (2001).","journal-title":"Cell"},{"key":"1467_CR90","first-page":"1","volume":"51","author":"S Choi","year":"2019","unstructured":"Choi, S., Cha, P.-H., Kim, H.-Y. & Choi, K.-Y. Indirubin-3\u2019-oxime stimulates chondrocyte maturation and longitudinal bone growth via activation of the Wnt\/\u03b2-catenin pathway. Exp. Mol. Med. 51, 1\u201310 (2019).","journal-title":"Exp. Mol. Med."},{"key":"1467_CR91","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1002\/jcp.30290","volume":"236","author":"J Li","year":"2021","unstructured":"Li, J. et al. Chemerin located in bone marrow promotes osteogenic differentiation and bone formation via Akt\/Gsk3\u03b2\/\u03b2-catenin axis in mice. J. Cell. Physiol. 236, 6042\u20136054 (2021).","journal-title":"J. Cell. Physiol."},{"key":"1467_CR92","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","volume":"16","author":"MJ Perugorria","year":"2019","unstructured":"Perugorria, M. J. et al. Wnt-\u03b2-catenin signalling in liver development, health and disease. Nat. Rev. Gastroenterol. Hepatol. 16, 121\u2013136 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1467_CR93","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/annrheumdis-2015-208577","volume":"76","author":"G Nalesso","year":"2017","unstructured":"Nalesso, G. et al. WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis. Ann. Rheum. Dis. 76, 218\u2013226 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1467_CR94","doi-asserted-by":"publisher","first-page":"687551","DOI":"10.3389\/fimmu.2021.687551","volume":"12","author":"D Wu","year":"2021","unstructured":"Wu, D. et al. T-cell mediated inflammation in postmenopausal osteoporosis. Front. Immunol. 12, 687551 (2021).","journal-title":"Front. Immunol."},{"key":"1467_CR95","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/jbmr.1588","volume":"27","author":"K Sj\u00f6gren","year":"2012","unstructured":"Sj\u00f6gren, K. et al. The gut microbiota regulates bone mass in mice. J. Bone Miner. Res. 27, 1357\u20131367 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR96","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt, A. & Chiricozzi, A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin. Rev. Allergy Immunol. 55, 379\u2013390 (2018).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1467_CR97","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","volume":"117","author":"A Taylor","year":"2006","unstructured":"Taylor, A., Verhagen, J., Blaser, K., Akdis, M. & Akdis, C. A. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 117, 433\u2013442 (2006).","journal-title":"Immunology"},{"key":"1467_CR98","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.immuni.2018.10.013","volume":"49","author":"AM Tyagi","year":"2018","unstructured":"Tyagi, A. M. et al. The microbial metabolite butyrate stimulates bone formation via T regulatory cell-mediated regulation of WNT10B expression. Immunity 49, 1116\u20131131.e7 (2018).","journal-title":"Immunity"},{"key":"1467_CR99","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fendo.2019.00578","volume":"10","author":"L Fischer","year":"2019","unstructured":"Fischer, L. et al. Foxp3+ regulatory T cells in bone and hematopoietic homeostasis. Front. Endocrinol. 10, 578 (2019).","journal-title":"Front. Endocrinol."},{"key":"1467_CR100","doi-asserted-by":"publisher","first-page":"35815","DOI":"10.1074\/jbc.M112.380493","volume":"287","author":"CE Runyan","year":"2012","unstructured":"Runyan, C. E., Liu, Z. & Schnaper, H. W. Phosphatidylinositol 3-kinase and Rab5 GTPase inversely regulate the Smad anchor for receptor activation (SARA) protein independently of transforming growth factor-\u03b21. J. Biol. Chem. 287, 35815\u201335824 (2012).","journal-title":"J. Biol. Chem."},{"key":"1467_CR101","doi-asserted-by":"publisher","first-page":"e44552","DOI":"10.1371\/journal.pone.0044552","volume":"7","author":"AM Tyagi","year":"2012","unstructured":"Tyagi, A. M. et al. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS ONE 7, e44552 (2012).","journal-title":"PLoS ONE"},{"key":"1467_CR102","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1172\/JCI128521","volume":"129","author":"MM Zaiss","year":"2019","unstructured":"Zaiss, M. M., Jones, R. M., Schett, G. & Pacifici, R. The gut-bone axis: how bacterial metabolites bridge the distance. J. Clin. Invest 129, 3018\u20133028 (2019).","journal-title":"J. Clin. Invest"},{"key":"1467_CR103","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1016\/j.bioactmat.2021.02.034","volume":"6","author":"X Yang","year":"2021","unstructured":"Yang, X. et al. T cell-depleting nanoparticles ameliorate bone loss by reducing activated T cells and regulating the Treg\/Th17 balance. Bioact. Mater. 6, 3150\u20133163 (2021).","journal-title":"Bioact. Mater."},{"key":"1467_CR104","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fbioe.2017.00068","volume":"5","author":"A Grosso","year":"2017","unstructured":"Grosso, A. et al. It takes two to tango: coupling of angiogenesis and osteogenesis for bone regeneration. Front. Bioeng. Biotechnol. 5, 68 (2017).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"1467_CR105","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature13145","volume":"507","author":"AP Kusumbe","year":"2014","unstructured":"Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323\u2013328 (2014).","journal-title":"Nature"},{"key":"1467_CR106","doi-asserted-by":"crossref","unstructured":"Aird, W. C. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ. Res. 100, 174\u2013190 (2007).","DOI":"10.1161\/01.RES.0000255690.03436.ae"},{"key":"1467_CR107","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature10783","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457\u2013462 (2012).","journal-title":"Nature"},{"key":"1467_CR108","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nm.3647","volume":"20","author":"A Mendelson","year":"2014","unstructured":"Mendelson, A. & Frenette, P. S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat. Med. 20, 833\u2013846 (2014).","journal-title":"Nat. Med."},{"key":"1467_CR109","doi-asserted-by":"crossref","unstructured":"Sivaraj, K. K. & Adams, R. H. Blood vessel formation and function in bone. Dev. Camb. Engl. 143, 2706\u20132715 (2016).","DOI":"10.1242\/dev.136861"},{"key":"1467_CR110","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.7150\/thno.50907","volume":"11","author":"X-F Hu","year":"2021","unstructured":"Hu, X.-F. et al. Impairment of type H vessels by NOX2-mediated endothelial oxidative stress: critical mechanisms and therapeutic targets for bone fragility in streptozotocin-induced type 1 diabetic mice. Theranostics 11, 3796\u20133812 (2021).","journal-title":"Theranostics"},{"key":"1467_CR111","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature13146","volume":"507","author":"SK Ramasamy","year":"2014","unstructured":"Ramasamy, S. K., Kusumbe, A. P., Wang, L. & Adams, R. H. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 507, 376\u2013380 (2014).","journal-title":"Nature"},{"key":"1467_CR112","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.7150\/thno.22144","volume":"8","author":"J Huang","year":"2018","unstructured":"Huang, J. et al. Harmine enhances type H vessel formation and prevents bone loss in ovariectomized mice. Theranostics 8, 2435\u20132446 (2018).","journal-title":"Theranostics"},{"key":"1467_CR113","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41591-018-0020-z","volume":"24","author":"R Xu","year":"2018","unstructured":"Xu, R. et al. Targeting skeletal endothelium to ameliorate bone loss. Nat. Med. 24, 823\u2013833 (2018).","journal-title":"Nat. Med."},{"key":"1467_CR114","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41556-019-0304-7","volume":"21","author":"SG Romeo","year":"2019","unstructured":"Romeo, S. G. et al. Endothelial proteolytic activity and interaction with non-resorbing osteoclasts mediate bone elongation. Nat. Cell Biol. 21, 430\u2013441 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1467_CR115","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7150\/thno.34126","volume":"10","author":"Y Peng","year":"2020","unstructured":"Peng, Y., Wu, S., Li, Y. & Crane, J. L. Type H blood vessels in bone modeling and remodeling. Theranostics 10, 426\u2013436 (2020).","journal-title":"Theranostics"},{"key":"1467_CR116","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.actbio.2022.07.015","volume":"150","author":"Y Zhuang","year":"2022","unstructured":"Zhuang, Y. et al. Small extracellular vesicles derived from hypoxic mesenchymal stem cells promote vascularized bone regeneration through the miR-210-3p\/EFNA3\/PI3K pathway. Acta Biomater. 150, 413\u2013426 (2022).","journal-title":"Acta Biomater."},{"key":"1467_CR117","doi-asserted-by":"publisher","unstructured":"Kaaij, M. H. et al. Increased type H blood vessels precedes pathological osteogenesis and inflammation in experimental spondyloarthritis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42449 (2023).","DOI":"10.1002\/art.42449"},{"key":"1467_CR118","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41413-022-00229-6","volume":"10","author":"Z Cui","year":"2022","unstructured":"Cui, Z. et al. Endothelial PDGF-BB\/PDGFR-\u03b2 signaling promotes osteoarthritis by enhancing angiogenesis-dependent abnormal subchondral bone formation. Bone Res. 10, 58 (2022).","journal-title":"Bone Res."},{"key":"1467_CR119","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrrheum.2010.70","volume":"6","author":"S Price","year":"2010","unstructured":"Price, S. Comparing the structural effects of denosumab and alendronate. Nat. Rev. Rheumatol. 6, 312\u2013312 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1467_CR120","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy, O., Stoll, D., Aubry-Rozier, B. & Rodriguez, E. G. Stopping denosumab. Curr. Osteoporos. Rep. 17, 8\u201315 (2019).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1467_CR121","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","volume":"49","author":"FH Ebetino","year":"2011","unstructured":"Ebetino, F. H. et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49, 20\u201333 (2011).","journal-title":"Bone"},{"key":"1467_CR122","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta, M. B. et al. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos. Int. 29, 41\u201347 (2018).","journal-title":"Osteoporos. Int."},{"key":"1467_CR123","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling, A. S., Harsl\u00f8f, T. & Langdahl, B. Treatment With zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J. Bone Miner. Res. 36, 1245\u20131254 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.368","volume":"11","author":"YJ Ko","year":"2021","unstructured":"Ko, Y. J. et al. A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor. Clin. Transl. Med. 11, e368 (2021).","journal-title":"Clin. Transl. Med."},{"key":"1467_CR125","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrrheum.2017.22","volume":"13","author":"M Croft","year":"2017","unstructured":"Croft, M. & Siegel, R. M. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat. Rev. Rheumatol. 13, 217\u2013233 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1467_CR126","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","volume":"40","author":"T Ono","year":"2020","unstructured":"Ono, T., Hayashi, M., Sasaki, F. & Nakashima, T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm. Regen. 40, 2 (2020).","journal-title":"Inflamm. Regen."},{"key":"1467_CR127","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jbspin.2007.05.004","volume":"75","author":"A Fouque-Aubert","year":"2008","unstructured":"Fouque-Aubert, A. & Chapurlat, R. Influence of RANKL inhibition on immune system in the treatment of bone diseases. Jt. Bone Spine 75, 5\u201310 (2008).","journal-title":"Jt. Bone Spine"},{"key":"1467_CR128","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s42255-019-0104-1","volume":"1","author":"T Asano","year":"2019","unstructured":"Asano, T. et al. Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone. Nat. Metab. 1, 868\u2013875 (2019).","journal-title":"Nat. Metab."},{"key":"1467_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05244-y","volume":"9","author":"J Xiong","year":"2018","unstructured":"Xiong, J. et al. Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat. Commun. 9, 2909 (2018).","journal-title":"Nat. Commun."},{"key":"1467_CR130","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1096\/fj.201700919RRR","volume":"32","author":"J Delgado-Calle","year":"2018","unstructured":"Delgado-Calle, J. et al. MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production. FASEB J. 32, 2878\u20132890 (2018).","journal-title":"FASEB J."},{"key":"1467_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33006-4","volume":"13","author":"D Huang","year":"2022","unstructured":"Huang, D. et al. Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis. Nat. Commun. 13, 5338 (2022).","journal-title":"Nat. Commun."},{"key":"1467_CR132","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jbmr.2342","volume":"30","author":"S Reppe","year":"2015","unstructured":"Reppe, S. et al. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. J. Bone Miner. Res. 30, 249\u2013256 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR133","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","volume":"77","author":"C Prather","year":"2020","unstructured":"Prather, C., Adams, E. & Zentgraf, W. Romosozumab: a first-in-class sclerostin inhibitor for osteoporosis. Am. J. Health Syst. Pharm. 77, 1949\u20131956 (2020).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"1467_CR134","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3389\/fendo.2019.00924","volume":"10","author":"SH Ralston","year":"2019","unstructured":"Ralston, S. H. & Gaston, M. S. Management of osteogenesis imperfecta. Front. Endocrinol. 10, 924 (2019).","journal-title":"Front. Endocrinol."},{"key":"1467_CR135","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4155\/bio-2017-0289","volume":"10","author":"D Zhang","year":"2018","unstructured":"Zhang, D., Yang, C., Chen, X., Li, X. & Zhong, D. A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222. Bioanalysis 10, 1115\u20131127 (2018).","journal-title":"Bioanalysis"},{"key":"1467_CR136","doi-asserted-by":"publisher","first-page":"e62295","DOI":"10.1371\/journal.pone.0062295","volume":"8","author":"M van Dinther","year":"2013","unstructured":"van Dinther, M. et al. Anti-Sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt\/LRP6 signaling. PLoS ONE 8, e62295 (2013).","journal-title":"PLoS ONE"},{"key":"1467_CR137","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377, 1417\u20131427 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR138","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR139","doi-asserted-by":"publisher","first-page":"eaay6570","DOI":"10.1126\/scitranslmed.aay6570","volume":"12","author":"J Bovijn","year":"2020","unstructured":"Bovijn, J. et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci. Transl. Med. 12, eaay6570 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1467_CR140","first-page":"252","volume":"35","author":"Y Yu","year":"2020","unstructured":"Yu, Y. et al. Sclerostin loop3: a potential target for developing a next generation sclerostin inhibitor for bone anabolic therapy with low cardiovascular concern. J. Bone Miner. Res. 35, 252\u2013252 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR141","doi-asserted-by":"publisher","first-page":"10890","DOI":"10.1074\/jbc.M807994200","volume":"284","author":"V Veverka","year":"2009","unstructured":"Veverka, V. et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890\u201310900 (2009).","journal-title":"J. Biol. Chem."},{"key":"1467_CR142","doi-asserted-by":"publisher","first-page":"e81710","DOI":"10.1371\/journal.pone.0081710","volume":"8","author":"V Boschert","year":"2013","unstructured":"Boschert, V. et al. Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition. PLoS ONE 8, e81710 (2013).","journal-title":"PLoS ONE"},{"key":"1467_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31997-8","volume":"13","author":"Y Yu","year":"2022","unstructured":"Yu, Y. et al. Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nat. Commun. 13, 4241 (2022).","journal-title":"Nat. Commun."},{"key":"1467_CR144","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.7150\/thno.63177","volume":"12","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice. Theranostics 12, 5645\u20135674 (2022).","journal-title":"Theranostics"},{"key":"1467_CR145","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","volume":"37","author":"SM Krishna","year":"2017","unstructured":"Krishna, S. M. et al. Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 37, 553\u2013566 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1467_CR146","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.cell.2018.10.025","volume":"175","author":"H Kim","year":"2018","unstructured":"Kim, H. et al. Irisin mediates effects on bone and fat via \u03b1V integrin receptors. Cell 175, 1756\u20131768.e17 (2018).","journal-title":"Cell"},{"key":"1467_CR147","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jbmr.3944","volume":"35","author":"G Storlino","year":"2020","unstructured":"Storlino, G. et al. Irisin prevents disuse-induced osteocyte apoptosis. J. Bone Miner. Res. 35, 766\u2013775 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR148","doi-asserted-by":"publisher","first-page":"572","DOI":"10.7150\/ijbs.63505","volume":"18","author":"Y Xue","year":"2022","unstructured":"Xue, Y. et al. Myokine Irisin promotes osteogenesis by activating BMP\/SMAD signaling via \u03b1V integrin and regulates bone mass in mice. Int. J. Biol. Sci. 18, 572\u2013584 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"1467_CR149","doi-asserted-by":"publisher","first-page":"12157","DOI":"10.1073\/pnas.1516622112","volume":"112","author":"G Colaianni","year":"2015","unstructured":"Colaianni, G. et al. The myokine irisin increases cortical bone mass. Proc. Natl Acad. Sci. USA 112, 12157\u201312162 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR150","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1093\/eurheartj\/ehac431","volume":"43","author":"C Chi","year":"2022","unstructured":"Chi, C. et al. Exerkine fibronectin type-III domain-containing protein 5\/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability. Eur. Heart J. 43, 4579\u20134595 (2022).","journal-title":"Eur. Heart J."},{"key":"1467_CR151","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1210\/endrev\/bnab005","volume":"42","author":"TJ Martin","year":"2021","unstructured":"Martin, T. J., Sims, N. A. & Seeman, E. Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor, PTH1R. Endocr. Rev. 42, 383\u2013406 (2021).","journal-title":"Endocr. Rev."},{"key":"1467_CR152","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1124\/jpet.112.199752","volume":"345","author":"ME Cupp","year":"2013","unstructured":"Cupp, M. E., Nayak, S. K., Adem, A. S. & Thomsen, W. J. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J. Pharmacol. Exp. Ther. 345, 404\u2013418 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1467_CR153","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1126\/science.aav7942","volume":"364","author":"L-H Zhao","year":"2019","unstructured":"Zhao, L.-H. et al. Structure and dynamics of the active human parathyroid hormone receptor-1. Science 364, 148\u2013153 (2019).","journal-title":"Science"},{"key":"1467_CR154","doi-asserted-by":"publisher","first-page":"e2122037119","DOI":"10.1073\/pnas.2122037119","volume":"119","author":"K Nemec","year":"2022","unstructured":"Nemec, K. et al. Functional modulation of PTH1R activation and signaling by RAMP2. Proc. Natl Acad. Sci. USA 119, e2122037119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR155","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1210\/me.2007-0274","volume":"22","author":"T Dean","year":"2008","unstructured":"Dean, T., Vilardaga, J.-P., Potts, J. T. & Gardella, T. J. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH\/PTHrP receptor. Mol. Endocrinol. 22, 156\u2013166 (2008).","journal-title":"Mol. Endocrinol."},{"key":"1467_CR156","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley, G., Dean, T., Corbin, B. A., Bahar, H. & Gardella, T. J. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157, 141\u2013149 (2016).","journal-title":"Endocrinology"},{"key":"1467_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34009-x","volume":"13","author":"X Zhai","year":"2022","unstructured":"Zhai, X. et al. Molecular insights into the distinct signaling duration for the peptide-induced PTH1R activation. Nat. Commun. 13, 6276 (2022).","journal-title":"Nat. Commun."},{"key":"1467_CR158","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.tem.2016.10.007","volume":"28","author":"NJ Pavlos","year":"2017","unstructured":"Pavlos, N. J. & Friedman, P. A. GPCR signaling and trafficking: the long and short of it. Trends Endocrinol. Metab. 28, 213\u2013226 (2017).","journal-title":"Trends Endocrinol. Metab."},{"key":"1467_CR159","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/jbmr.1978","volume":"28","author":"MJ Horwitz","year":"2013","unstructured":"Horwitz, M. J. et al. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J. Bone Miner. Res. 28, 2266\u20132276 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR160","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1210\/en.2002-220467","volume":"143","author":"X Feng","year":"2002","unstructured":"Feng, X. et al. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. Endocrinology 143, 4868\u20134874 (2002).","journal-title":"Endocrinology"},{"key":"1467_CR161","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1084\/jem.190.12.1741","volume":"190","author":"F Arai","year":"1999","unstructured":"Arai, F. et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 190, 1741\u20131754 (1999).","journal-title":"J. Exp. Med"},{"key":"1467_CR162","doi-asserted-by":"publisher","first-page":"613975","DOI":"10.3389\/fimmu.2020.613975","volume":"11","author":"S Fuentelsaz-Romero","year":"2020","unstructured":"Fuentelsaz-Romero, S. et al. GM-CSF expression and macrophage polarization in joints of undifferentiated arthritis patients evolving to rheumatoid arthritis or psoriatic arthritis. Front. Immunol. 11, 613975 (2020).","journal-title":"Front. Immunol."},{"key":"1467_CR163","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/boneres.2017.22","volume":"5","author":"G-Q Yao","year":"2017","unstructured":"Yao, G.-Q., Troiano, N., Simpson, C. A. & Insogna, K. L. Selective deletion of the soluble colony-stimulating factor 1 isoform in vivo prevents estrogen-deficiency bone loss in mice. Bone Res. 5, 17022 (2017).","journal-title":"Bone Res."},{"key":"1467_CR164","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1189\/jlb.2A0114-006R","volume":"96","author":"KA Sauter","year":"2014","unstructured":"Sauter, K. A. et al. Pleiotropic effects of extended blockade of CSF1R signaling in adult mice. J. Leukoc. Biol. 96, 265\u2013274 (2014).","journal-title":"J. Leukoc. Biol."},{"key":"1467_CR165","doi-asserted-by":"publisher","first-page":"e67772","DOI":"10.7554\/eLife.67772","volume":"10","author":"C-C Tang","year":"2021","unstructured":"Tang, C.-C. et al. Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. eLife 10, e67772 (2021).","journal-title":"eLife"},{"key":"1467_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13176","volume":"7","author":"MN Wein","year":"2016","unstructured":"Wein, M. N. et al. SIKs control osteocyte responses to parathyroid hormone. Nat. Commun. 7, 13176 (2016).","journal-title":"Nat. Commun."},{"key":"1467_CR167","doi-asserted-by":"publisher","first-page":"e2002979","DOI":"10.1371\/journal.pbio.2002979","volume":"16","author":"Y Zur","year":"2018","unstructured":"Zur, Y. et al. A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and \u03b1v\u03b23 integrin for osteoporosis therapy. PLoS Biol. 16, e2002979 (2018).","journal-title":"PLoS Biol."},{"key":"1467_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"X Pang","year":"2023","unstructured":"Pang, X. et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct. Target. Ther. 8, 1 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1467_CR169","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1073\/pnas.82.17.5766","volume":"82","author":"R Pytela","year":"1985","unstructured":"Pytela, R., Pierschbacher, M. D. & Ruoslahti, E. A 125\/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc. Natl Acad. Sci. USA 82, 5766\u20135770 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR170","first-page":"127","volume":"1","author":"TJ Chambers","year":"1986","unstructured":"Chambers, T. J., Fuller, K., Darby, J. A., Pringle, J. A. & Horton, M. A. Monoclonal antibodies against osteoclasts inhibit bone resorption in vitro. Bone Min. 1, 127\u2013135 (1986).","journal-title":"Bone Min."},{"key":"1467_CR171","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1083\/jcb.111.4.1713","volume":"111","author":"M Sato","year":"1990","unstructured":"Sato, M. et al. Echistatin is a potent inhibitor of bone resorption in culture. J. Cell Biol. 111, 1713\u20131723 (1990).","journal-title":"J. Cell Biol."},{"key":"1467_CR172","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1210\/jc.2004-2126","volume":"90","author":"MG Murphy","year":"2005","unstructured":"Murphy, M. G. et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 90, 2022\u20132028 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1467_CR173","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.biomaterials.2016.05.007","volume":"98","author":"D Park","year":"2016","unstructured":"Park, D. et al. A novel small-molecule PPI inhibitor targeting integrin \u03b1v\u03b23-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice. Biomaterials 98, 131\u2013142 (2016).","journal-title":"Biomaterials"},{"key":"1467_CR174","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41422-018-0070-2","volume":"28","author":"D Liu","year":"2018","unstructured":"Liu, D. et al. Circulating apoptotic bodies maintain mesenchymal stem cell homeostasis and ameliorate osteopenia via transferring multiple cellular factors. Cell Res. 28, 918\u2013933 (2018).","journal-title":"Cell Res."},{"key":"1467_CR175","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1359\/jbmr.2005.20.1.58","volume":"20","author":"NE Lane","year":"2005","unstructured":"Lane, N. E. et al. Mice lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. J. Bone Miner. Res. 20, 58\u201366 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR176","doi-asserted-by":"crossref","unstructured":"Dufour, C., Holy, X. & Marie, P. J. Skeletal unloading induces osteoblast apoptosis and targets alpha5beta1-PI3K-Bcl-2 signaling in rat bone. Exp. Cell Res. 313, 394\u2013403 (2007).","DOI":"10.1016\/j.yexcr.2006.10.021"},{"key":"1467_CR177","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41413-020-00126-w","volume":"9","author":"MA Riquelme","year":"2021","unstructured":"Riquelme, M. A., Gu, S., Hua, R. & Jiang, J. X. Mechanotransduction via the coordinated actions of integrins, PI3K signaling and Connexin hemichannels. Bone Res. 9, 8 (2021).","journal-title":"Bone Res."},{"key":"1467_CR178","doi-asserted-by":"publisher","first-page":"H1370","DOI":"10.1152\/ajpheart.00523.2005","volume":"290","author":"VFM Segers","year":"2006","unstructured":"Segers, V. F. M. et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am. J. Physiol. Heart Circ. Physiol. 290, H1370\u2013H1377 (2006).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1467_CR179","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1186\/ar2391","volume":"10","author":"Q Zhang","year":"2008","unstructured":"Zhang, Q., Guo, R., Schwarz, E. M., Boyce, B. F. & Xing, L. TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. Arthritis Res. Ther. 10, R37 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"1467_CR180","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00296-010-1634-8","volume":"31","author":"J Kikuta","year":"2011","unstructured":"Kikuta, J., Iwai, K., Saeki, Y. & Ishii, M. S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol. Int. 31, 967\u2013969 (2011).","journal-title":"Rheumatol. Int."},{"key":"1467_CR181","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06249.x","volume":"1240","author":"TJ Chambers","year":"2011","unstructured":"Chambers, T. J. & Fuller, K. How are osteoclasts induced to resorb bone? Ann. N. Y. Acad. Sci. 1240, 1\u20136 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1467_CR182","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/jcb.21171","volume":"101","author":"DP Trebec","year":"2007","unstructured":"Trebec, D. P. et al. Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J. Cell. Biochem. 101, 205\u2013220 (2007).","journal-title":"J. Cell. Biochem."},{"key":"1467_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6215","volume":"5","author":"J Keller","year":"2014","unstructured":"Keller, J. et al. Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat. Commun. 5, 5215 (2014).","journal-title":"Nat. Commun."},{"key":"1467_CR184","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.3390\/ijms23105630","volume":"23","author":"T Ishii","year":"2022","unstructured":"Ishii, T. et al. Locally secreted semaphorin 4D is engaged in both pathogenic bone resorption and retarded bone regeneration in a ligature-induced mouse model of periodontitis. Int. J. Mol. Sci. 23, 5630 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1467_CR185","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1177\/0022034514552676","volume":"93","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y., Wei, L., Miron, R. J., Zhang, Q. & Bian, Z. Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J. Dent. Res. 93, 1095\u20131100 (2014).","journal-title":"J. Dent. Res."},{"key":"1467_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/srep26925","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., Wei, L., Miron, R. J., Shi, B. & Bian, Z. Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects. Sci. Rep. 6, 26925 (2016).","journal-title":"Sci. Rep."},{"key":"1467_CR187","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.chembiol.2016.09.015","volume":"23","author":"Y Matsunaga","year":"2016","unstructured":"Matsunaga, Y., Bashiruddin, N. K., Kitago, Y., Takagi, J. & Suga, H. Allosteric inhibition of a semaphorin 4D receptor plexin B1 by a high-affinity macrocyclic peptide. Cell Chem. Biol. 23, 1341\u20131350 (2016).","journal-title":"Cell Chem. Biol."},{"key":"1467_CR188","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.cmet.2018.12.021","volume":"29","author":"M Hayashi","year":"2019","unstructured":"Hayashi, M. et al. Autoregulation of osteocyte Sema3A orchestrates estrogen action and counteracts bone aging. Cell Metab. 29, 627\u2013637.e5 (2019).","journal-title":"Cell Metab."},{"key":"1467_CR189","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature12115","volume":"497","author":"T Fukuda","year":"2013","unstructured":"Fukuda, T. et al. Sema3A regulates bone-mass accrual through sensory innervations. Nature 497, 490\u2013493 (2013).","journal-title":"Nature"},{"key":"1467_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/srep24562","volume":"6","author":"X Ma","year":"2016","unstructured":"Ma, X. et al. Naringin ameliorates bone loss induced by sciatic neurectomy and increases Semaphorin 3A expression in denervated bone. Sci. Rep. 6, 24562 (2016).","journal-title":"Sci. Rep."},{"key":"1467_CR191","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14728222.2014.983078","volume":"19","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis, A. D. et al. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opin. Ther. Targets 19, 299\u2013306 (2015).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1467_CR192","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.it.2012.01.008","volume":"33","author":"H Takamatsu","year":"2012","unstructured":"Takamatsu, H. & Kumanogoh, A. Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol. 33, 127\u2013135 (2012).","journal-title":"Trends Immunol."},{"key":"1467_CR193","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrm.2015.16","volume":"17","author":"A Kania","year":"2016","unstructured":"Kania, A. & Klein, R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat. Rev. Mol. Cell Biol. 17, 240\u2013256 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1467_CR194","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","volume":"4","author":"C Zhao","year":"2006","unstructured":"Zhao, C. et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4, 111\u2013121 (2006).","journal-title":"Cell Metab."},{"key":"1467_CR195","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1359\/jbmr.080324","volume":"23","author":"EH Allan","year":"2008","unstructured":"Allan, E. H. et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J. Bone Miner. Res.23, 1170\u20131181 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR196","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/jbmr.1820","volume":"28","author":"FM Takyar","year":"2013","unstructured":"Takyar, F. M. et al. EphrinB2\/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J. Bone Miner. Res. 28, 912\u2013925 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR197","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/jbmr.2084","volume":"29","author":"V Stiffel","year":"2014","unstructured":"Stiffel, V., Amoui, M., Sheng, M. H.-C., Mohan, S. & Lau, K.-H. W. EphA4 receptor is a novel negative regulator of osteoclast activity. J. Bone Miner. Res. 29, 804\u2013819 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR198","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/jbmr.3479","volume":"33","author":"S Yang","year":"2018","unstructured":"Yang, S. et al. Suppression of bone resorption by miR-141 in aged rhesus monkeys. J. Bone Miner. Res. 33, 1799\u20131812 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR199","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.7717\/peerj-achem.4","volume":"2","author":"K Igami","year":"2020","unstructured":"Igami, K. et al. Characterization and function of medium and large extracellular vesicles from plasma and urine by surface antigens and Annexin V. PeerJ Anal. Chem. 2, e4 (2020).","journal-title":"PeerJ Anal. Chem."},{"key":"1467_CR200","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s43587-021-00050-6","volume":"1","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Exosomal transfer of osteoclast-derived miRNAs to chondrocytes contributes to osteoarthritis progression. Nat. Aging 1, 368\u2013384 (2021).","journal-title":"Nat. Aging"},{"key":"1467_CR201","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcb.22228","volume":"109","author":"F Mizoguchi","year":"2010","unstructured":"Mizoguchi, F. et al. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J. Cell. Biochem. 109, 866\u2013875 (2010).","journal-title":"J. Cell. Biochem."},{"key":"1467_CR202","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ncb2000","volume":"12","author":"M Ostrowski","year":"2010","unstructured":"Ostrowski, M. et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19\u201330 (2010). ; sup pp 1-13.","journal-title":"Nat. Cell Biol."},{"key":"1467_CR203","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.omtn.2022.07.008","volume":"29","author":"AA John","year":"2022","unstructured":"John, A. A. et al. AAV-mediated delivery of osteoblast\/osteoclast-regulating miRNAs for osteoporosis therapy. Mol. Ther. Nucleic Acids 29, 296\u2013311 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1467_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06446-0","volume":"9","author":"K Inoue","year":"2018","unstructured":"Inoue, K. et al. Bone protection by inhibition of microRNA-182. Nat. Commun. 9, 4108 (2018).","journal-title":"Nat. Commun."},{"key":"1467_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01267-2","volume":"20","author":"N Wang","year":"2022","unstructured":"Wang, N. et al. Increased BMSC exosomal miR-140-3p alleviates bone degradation and promotes bone restoration by targeting Plxnb1 in diabetic rats. J. Nanobiotechnol. 20, 97 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"1467_CR206","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41368-021-00148-y","volume":"13","author":"H Zheng","year":"2021","unstructured":"Zheng, H. et al. miR-140-3p enhanced the osteo\/odontogenic differentiation of DPSCs via inhibiting KMT5B under hypoxia condition. Int. J. Oral. Sci. 13, 41 (2021).","journal-title":"Int. J. Oral. Sci."},{"key":"1467_CR207","doi-asserted-by":"publisher","first-page":"e12794","DOI":"10.1111\/acel.12794","volume":"17","author":"R Xu","year":"2018","unstructured":"Xu, R. et al. MicroRNA-31a-5p from aging BMSCs links bone formation and resorption in the aged bone marrow microenvironment. Aging Cell 17, e12794 (2018).","journal-title":"Aging Cell"},{"key":"1467_CR208","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1021\/acs.nanolett.9b00287","volume":"19","author":"H Song","year":"2019","unstructured":"Song, H. et al. Reversal of osteoporotic activity by endothelial cell-secreted bone targeting and biocompatible exosomes. Nano Lett. 19, 3040\u20133048 (2019).","journal-title":"Nano Lett."},{"key":"1467_CR209","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.3390\/cells10123274","volume":"10","author":"MMJ Amin","year":"2021","unstructured":"Amin, M. M. J., Trevelyan, C. J. & Turner, N. A. MicroRNA-214 in health and disease. Cells 10, 3274 (2021).","journal-title":"Cells"},{"key":"1467_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10809-6","volume":"10","author":"Y-S Yang","year":"2019","unstructured":"Yang, Y.-S. et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat. Commun. 10, 2958 (2019).","journal-title":"Nat. Commun."},{"key":"1467_CR211","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1172\/JCI10158","volume":"106","author":"W Zhao","year":"2000","unstructured":"Zhao, W., Byrne, M. H., Wang, Y. & Krane, S. M. Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J. Clin. Invest. 106, 941\u2013949 (2000).","journal-title":"J. Clin. Invest."},{"key":"1467_CR212","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1242\/jcs.01581","volume":"118","author":"K Holmbeck","year":"2005","unstructured":"Holmbeck, K. et al. The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J. Cell Sci. 118, 147\u2013156 (2005).","journal-title":"J. Cell Sci."},{"key":"1467_CR213","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bone.2015.02.016","volume":"75","author":"PR Buenzli","year":"2015","unstructured":"Buenzli, P. R. & Sims, N. A. Quantifying the osteocyte network in the human skeleton. Bone 75, 144\u2013150 (2015).","journal-title":"Bone"},{"key":"1467_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26571-7","volume":"12","author":"JS Wang","year":"2021","unstructured":"Wang, J. S. et al. Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin. Nat. Commun. 12, 6271 (2021).","journal-title":"Nat. Commun."},{"key":"1467_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28318-4","volume":"13","author":"JC Lui","year":"2022","unstructured":"Lui, J. C. et al. A neomorphic variant in SP7 alters sequence specificity and causes a high-turnover bone disorder. Nat. Commun. 13, 700 (2022).","journal-title":"Nat. Commun."},{"key":"1467_CR216","doi-asserted-by":"publisher","first-page":"E1694","DOI":"10.3390\/ijms20071694","volume":"20","author":"T Komori","year":"2019","unstructured":"Komori, T. Regulation of proliferation, differentiation and functions of osteoblasts by Runx2. Int. J. Mol. Sci. 20, E1694 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1467_CR217","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4252\/wjsc.v5.i4.136","volume":"5","author":"M Fakhry","year":"2013","unstructured":"Fakhry, M., Hamade, E., Badran, B., Buchet, R. & Magne, D. Molecular mechanisms of mesenchymal stem cell differentiation towards osteoblasts. World J. Stem Cells 5, 136\u2013148 (2013).","journal-title":"World J. Stem Cells"},{"key":"1467_CR218","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s12276-020-0471-4","volume":"52","author":"W-J Kim","year":"2020","unstructured":"Kim, W.-J., Shin, H.-L., Kim, B.-S., Kim, H.-J. & Ryoo, H.-M. RUNX2-modifying enzymes: therapeutic targets for bone diseases. Exp. Mol. Med. 52, 1178\u20131184 (2020).","journal-title":"Exp. Mol. Med."},{"key":"1467_CR219","doi-asserted-by":"publisher","first-page":"109504","DOI":"10.1016\/j.cellsig.2019.109504","volume":"70","author":"J-X Yang","year":"2020","unstructured":"Yang, J.-X., Xie, P., Li, Y.-S., Wen, T. & Yang, X.-C. Osteoclast-derived miR-23a-5p-containing exosomes inhibit osteogenic differentiation by regulating Runx2. Cell. Signal. 70, 109504 (2020).","journal-title":"Cell. Signal."},{"key":"1467_CR220","first-page":"7766","volume":"23","author":"F Cheng","year":"2019","unstructured":"Cheng, F., Yang, M.-M. & Yang, R.-H. MiRNA-365a-3p promotes the progression of osteoporosis by inhibiting osteogenic differentiation via targeting RUNX2. Eur. Rev. Med. Pharmacol. Sci. 23, 7766\u20137774 (2019).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"1467_CR221","doi-asserted-by":"publisher","first-page":"116676","DOI":"10.1016\/j.lfs.2019.116676","volume":"232","author":"A Narayanan","year":"2019","unstructured":"Narayanan, A., Srinaath, N., Rohini, M. & Selvamurugan, N. Regulation of Runx2 by MicroRNAs in osteoblast differentiation. Life Sci. 232, 116676 (2019).","journal-title":"Life Sci."},{"key":"1467_CR222","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/emboj.2009.23","volume":"28","author":"CA de Frutos","year":"2009","unstructured":"de Frutos, C. A. et al. Snail1 controls bone mass by regulating Runx2 and VDR expression during osteoblast differentiation. EMBO J. 28, 686\u2013696 (2009).","journal-title":"EMBO J."},{"key":"1467_CR223","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.gene.2005.10.017","volume":"366","author":"S-C Bae","year":"2006","unstructured":"Bae, S.-C. & Lee, Y. H. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 366, 58\u201366 (2006).","journal-title":"Gene"},{"key":"1467_CR224","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41374-018-0149-x","volume":"99","author":"Z Hou","year":"2019","unstructured":"Hou, Z. et al. KLF2 regulates osteoblast differentiation by targeting of Runx2. Lab. Investig. J. Tech. Methods Pathol. 99, 271\u2013280 (2019).","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"1467_CR225","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41388-022-02529-x","volume":"42","author":"VL Tippett","year":"2023","unstructured":"Tippett, V. L. et al. The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review. Oncogene 42, 259\u2013277 (2023).","journal-title":"Oncogene"},{"key":"1467_CR226","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.3390\/cancers13174284","volume":"13","author":"KJ Synoradzki","year":"2021","unstructured":"Synoradzki, K. J. et al. TP53 in biology and treatment of osteosarcoma. Cancers 13, 4284 (2021).","journal-title":"Cancers"},{"key":"1467_CR227","doi-asserted-by":"publisher","first-page":"e2117857119","DOI":"10.1073\/pnas.2117857119","volume":"119","author":"J Tu","year":"2022","unstructured":"Tu, J. et al. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proc. Natl Acad. Sci. USA 119, e2117857119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR228","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","volume":"7","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7, 104\u2013112 (2014).","journal-title":"Cell Rep."},{"key":"1467_CR229","doi-asserted-by":"publisher","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali, P. G. et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv79\u2013iv95 (2018).","journal-title":"Ann. Oncol."},{"key":"1467_CR230","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/annonc\/mdw009","volume":"27","author":"M Bousquet","year":"2016","unstructured":"Bousquet, M. et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. Ann. Oncol. 27, 738\u2013744 (2016).","journal-title":"Ann. Oncol."},{"key":"1467_CR231","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO;2-3","volume":"92","author":"N Gokgoz","year":"2001","unstructured":"Gokgoz, N. et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 92, 2181\u20132189 (2001).","journal-title":"Cancer"},{"key":"1467_CR232","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1101\/gad.1656808","volume":"22","author":"CR Walkley","year":"2008","unstructured":"Walkley, C. R. et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 22, 1662\u20131676 (2008).","journal-title":"Genes Dev."},{"key":"1467_CR233","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1073\/pnas.0805462105","volume":"105","author":"SD Berman","year":"2008","unstructured":"Berman, S. D. et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc. Natl Acad. Sci. USA 105, 11851\u201311856 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR234","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman, D. A. et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J. Clin. Oncol. 39, 1584\u20131594 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1467_CR235","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-15-1015","volume":"22","author":"M Verreault","year":"2016","unstructured":"Verreault, M. et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas. Clin. Cancer Res. 22, 1185\u20131196 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1467_CR236","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1158\/1078-0432.CCR-18-1580","volume":"25","author":"A Berberich","year":"2019","unstructured":"Berberich, A. et al. Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib. Clin. Cancer Res. 25, 253\u2013265 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1467_CR237","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pharmthera.2019.06.010","volume":"202","author":"E Thoenen","year":"2019","unstructured":"Thoenen, E., Curl, A. & Iwakuma, T. TP53 in bone and soft tissue sarcomas. Pharmacol. Ther. 202, 149\u2013164 (2019).","journal-title":"Pharmacol. Ther."},{"key":"1467_CR238","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-12-2293","volume":"19","author":"Y Pignochino","year":"2013","unstructured":"Pignochino, Y. et al. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin. Cancer Res. 19, 2117\u20132131 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1467_CR239","first-page":"27","volume":"36","author":"JA Buckwalter","year":"1987","unstructured":"Buckwalter, J. A. & Cooper, R. R. Bone structure and function. Instr. Course Lect. 36, 27\u201348 (1987).","journal-title":"Instr. Course Lect."},{"key":"1467_CR240","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-007-0462-5","volume":"19","author":"I Byrjalsen","year":"2008","unstructured":"Byrjalsen, I., Leeming, D. J., Qvist, P., Christiansen, C. & Karsdal, M. A. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos. Int. 19, 339\u2013348 (2008).","journal-title":"Osteoporos. Int."},{"key":"1467_CR241","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00223-009-9312-0","volume":"86","author":"DK Yarbrough","year":"2010","unstructured":"Yarbrough, D. K. et al. Specific binding and mineralization of calcified surfaces by small peptides. Calcif. Tissue Int. 86, 58\u201366 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"1467_CR242","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.joms.2014.07.004","volume":"72","author":"S Cheong","year":"2014","unstructured":"Cheong, S. et al. Bisphosphonate uptake in areas of tooth extraction or periapical disease. J. Oral. Maxillofac. Surg. 72, 2461\u20132468 (2014).","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"1467_CR243","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"N Gh","year":"2006","unstructured":"Gh, N. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38, 617\u2013627 (2006).","journal-title":"Bone"},{"key":"1467_CR244","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RGG Russell","year":"2008","unstructured":"Russell, R. G. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733\u2013759 (2008).","journal-title":"Osteoporos. Int."},{"key":"1467_CR245","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","volume":"9","author":"KB Farrell","year":"2018","unstructured":"Farrell, K. B., Karpeisky, A., Thamm, D. H. & Zinnen, S. Bisphosphonate conjugation for bone specific drug targeting. Bone Rep. 9, 47\u201360 (2018).","journal-title":"Bone Rep."},{"key":"1467_CR246","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1517\/17425247.2015.1021679","volume":"12","author":"DA Ossipov","year":"2015","unstructured":"Ossipov, D. A. Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering. Expert Opin. Drug Deliv. 12, 1443\u20131458 (2015).","journal-title":"Expert Opin. Drug Deliv."},{"key":"1467_CR247","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/acsnano.9b04571","volume":"14","author":"J Vanderburgh","year":"2020","unstructured":"Vanderburgh, J. et al. Tuning ligand density to optimize pharmacokinetics of targeted nanoparticles for dual protection against tumor-induced bone destruction. ACS Nano 14, 311\u2013327 (2020).","journal-title":"ACS Nano"},{"key":"1467_CR248","doi-asserted-by":"publisher","first-page":"9926","DOI":"10.1021\/jacs.2c02706","volume":"144","author":"L Xue","year":"2022","unstructured":"Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 9926\u20139937 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1467_CR249","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1111\/bph.15251","volume":"178","author":"S Sun","year":"2021","unstructured":"Sun, S. et al. Bisphosphonates for delivering drugs to bone. Br. J. Pharmacol. 178, 2008\u20132025 (2021).","journal-title":"Br. J. Pharmacol."},{"key":"1467_CR250","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jconrel.2022.08.034","volume":"350","author":"B Hu","year":"2022","unstructured":"Hu, B. et al. Research progress of bone-targeted drug delivery system on metastatic bone tumors. J. Control. Release 350, 377\u2013388 (2022).","journal-title":"J. Control. Release"},{"key":"1467_CR251","doi-asserted-by":"publisher","first-page":"eabf2051","DOI":"10.1126\/sciadv.abf2051","volume":"7","author":"Z Tian","year":"2021","unstructured":"Tian, Z. et al. Harnessing the power of antibodies to fight bone metastasis. Sci. Adv. 7, eabf2051 (2021).","journal-title":"Sci. Adv."},{"key":"1467_CR252","doi-asserted-by":"crossref","unstructured":"Guan, M. et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat. Med. 18, 456\u2013462 (2012).","DOI":"10.1038\/nm.2665"},{"key":"1467_CR253","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx, R. E., Sawatari, Y., Fortin, M. & Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral. Maxillofac. Surg. 63, 1567\u20131575 (2005).","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"1467_CR254","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1042\/BJ20130118","volume":"452","author":"MSC Wilson","year":"2013","unstructured":"Wilson, M. S. C., Livermore, T. M. & Saiardi, A. Inositol pyrophosphates: between signalling and metabolism. Biochem. J. 452, 369\u2013379 (2013).","journal-title":"Biochem. J."},{"key":"1467_CR255","doi-asserted-by":"publisher","first-page":"9465","DOI":"10.1158\/0008-5472.CAN-09-2805","volume":"69","author":"M Gu","year":"2009","unstructured":"Gu, M., Roy, S., Raina, K., Agarwal, C. & Agarwal, R. Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res. 69, 9465\u20139472 (2009).","journal-title":"Cancer Res."},{"key":"1467_CR256","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1159\/000341474","volume":"30","author":"MDM Arriero","year":"2012","unstructured":"Arriero, M. D. M., Ramis, J. M., Perell\u00f3, J. & Monjo, M. Differential response of MC3T3-E1 and human mesenchymal stem cells to inositol hexakisphosphate. Cell. Physiol. Biochem. 30, 974\u2013986 (2012).","journal-title":"Cell. Physiol. Biochem."},{"key":"1467_CR257","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.biomaterials.2018.12.024","volume":"194","author":"Z Zhou","year":"2019","unstructured":"Zhou, Z. et al. One stone with two birds: Phytic acid-capped platinum nanoparticles for targeted combination therapy of bone tumors. Biomaterials 194, 130\u2013138 (2019).","journal-title":"Biomaterials"},{"key":"1467_CR258","doi-asserted-by":"publisher","first-page":"e2004829","DOI":"10.1002\/smll.202004829","volume":"16","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. Carrier-free platinum nanomedicine for targeted cancer therapy. Small 16, e2004829 (2020).","journal-title":"Small"},{"key":"1467_CR259","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3390\/nu13082859","volume":"13","author":"P Sanchis","year":"2021","unstructured":"Sanchis, P. et al. Understanding the protective effect of phytate in bone decalcification related-diseases. Nutrients 13, 2859 (2021).","journal-title":"Nutrients"},{"key":"1467_CR260","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/009127006100100503","volume":"1","author":"HM Frost","year":"1961","unstructured":"Frost, H. M., Villanueva, A. R., Roth, H. & Stanisavljevic, S. Tetracycline bone labeling. J. N. Drugs 1, 206\u2013216 (1961).","journal-title":"J. N. Drugs"},{"key":"1467_CR261","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/BF00305526","volume":"54","author":"M Cochran","year":"1994","unstructured":"Cochran, M., Cochran, M., Neville, A. & Marshall, E. A. Comparison of bone formation rates measured by radiocalcium kinetics and double-tetracycline labeling in maintenance dialysis patients. Calcif. Tissue Int. 54, 392\u2013398 (1994).","journal-title":"Calcif. Tissue Int."},{"key":"1467_CR262","doi-asserted-by":"publisher","first-page":"116377","DOI":"10.1016\/j.bone.2022.116377","volume":"159","author":"AJ Warner","year":"2022","unstructured":"Warner, A. J., Hathaway-Schrader, J. D., Lubker, R., Davies, C. & Novince, C. M. Tetracyclines and bone: unclear actions with potentially lasting effects. Bone 159, 116377 (2022).","journal-title":"Bone"},{"key":"1467_CR263","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra, I. & Roberts, M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232\u2013260 (2001).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"1467_CR264","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jcis.2010.04.081","volume":"349","author":"J Wang","year":"2010","unstructured":"Wang, J., Hu, J. & Zhang, S. Studies on the sorption of tetracycline onto clays and marine sediment from seawater. J. Colloid Interface Sci. 349, 578\u2013582 (2010).","journal-title":"J. Colloid Interface Sci."},{"key":"1467_CR265","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/BF02405117","volume":"35","author":"HM Myers","year":"1983","unstructured":"Myers, H. M., Tochon-Danguy, H. J. & Baud, C. A. IR absorption spectrophotometric analysis of the complex formed by tetracycline and synthetic hydroxyapatite. Calcif. Tissue Int. 35, 745\u2013749 (1983).","journal-title":"Calcif. Tissue Int."},{"key":"1467_CR266","doi-asserted-by":"crossref","unstructured":"Neale, J. R. et al. Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg. Med. Chem. Lett. 19, 680\u2013683 (2009).","DOI":"10.1016\/j.bmcl.2008.12.051"},{"key":"1467_CR267","doi-asserted-by":"publisher","first-page":"17543","DOI":"10.1021\/jacs.0c07309","volume":"142","author":"X Lin","year":"2020","unstructured":"Lin, X. et al. Smart nanosacrificial layer on the bone surface prevents osteoporosis through acid-base neutralization regulated biocascade effects. J. Am. Chem. Soc. 142, 17543\u201317556 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"1467_CR268","doi-asserted-by":"publisher","first-page":"993095","DOI":"10.3389\/fphar.2022.993095","volume":"13","author":"Y Que","year":"2022","unstructured":"Que, Y., Yang, Y., Zafar, H. & Wang, D. Tetracycline-grafted mPEG-PLGA micelles for bone-targeting and osteoporotic improvement. Front. Pharmacol. 13, 993095 (2022).","journal-title":"Front. Pharmacol."},{"key":"1467_CR269","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbm.a.37279","volume":"110","author":"MA Ackun-Farmmer","year":"2022","unstructured":"Ackun-Farmmer, M. A., Xiao, B., Newman, M. R. & Benoit, D. S. W. Macrophage depletion increases target specificity of bone-targeted nanoparticles. J. Biomed. Mater. Res. A 110, 229\u2013238 (2022).","journal-title":"J. Biomed. Mater. Res. A"},{"key":"1467_CR270","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.2174\/138161210791920496","volume":"16","author":"J-W Yoo","year":"2010","unstructured":"Yoo, J.-W., Chambers, E. & Mitragotri, S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 16, 2298\u20132307 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"1467_CR271","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1229568","volume":"339","author":"PL Rodriguez","year":"2013","unstructured":"Rodriguez, P. L. et al. Minimal \u2018Self\u2019 peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971\u2013975 (2013).","journal-title":"Science"},{"key":"1467_CR272","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2013.04.004","volume":"38","author":"D Hashimoto","year":"2013","unstructured":"Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792\u2013804 (2013).","journal-title":"Immunity"},{"key":"1467_CR273","doi-asserted-by":"publisher","first-page":"141ra93","DOI":"10.1126\/scitranslmed.3003720","volume":"4","author":"JC Reichert","year":"2012","unstructured":"Reichert, J. C. et al. A tissue engineering solution for segmental defect regeneration in load-bearing long bones. Sci. Transl. Med. 4, 141ra93 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1467_CR274","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.archoralbio.2006.10.005","volume":"52","author":"PS Gomes","year":"2007","unstructured":"Gomes, P. S. & Fernandes, M. H. Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells. Arch. Oral. Biol. 52, 251\u2013259 (2007).","journal-title":"Arch. Oral. Biol."},{"key":"1467_CR275","doi-asserted-by":"publisher","first-page":"8819","DOI":"10.1073\/pnas.83.23.8819","volume":"83","author":"A Oldberg","year":"1986","unstructured":"Oldberg, A., Franz\u00e9n, A. & Heineg\u00e5rd, D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc. Natl Acad. Sci. USA 83, 8819\u20138823 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR276","doi-asserted-by":"crossref","unstructured":"Butler, W. T. The nature and significance of osteopontin. Connect. Tissue Res. 23, 123\u2013136 (1989).","DOI":"10.3109\/03008208909002412"},{"key":"1467_CR277","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF00296767","volume":"50","author":"JP Gorski","year":"1992","unstructured":"Gorski, J. P. Acidic phosphoproteins from bone matrix: a structural rationalization of their role in biomineralization. Calcif. Tissue Int. 50, 391\u2013396 (1992).","journal-title":"Calcif. Tissue Int."},{"key":"1467_CR278","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11914-020-00604-4","volume":"18","author":"JJ Nielsen","year":"2020","unstructured":"Nielsen, J. J. & Low, S. A. Bone-targeting systems to systemically deliver therapeutics to bone fractures for accelerated healing. Curr. Osteoporos. Rep. 18, 449\u2013459 (2020).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1467_CR279","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ijpharm.2014.08.067","volume":"475","author":"T Jiang","year":"2014","unstructured":"Jiang, T. et al. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications. Int. J. Pharm. 475, 547\u2013557 (2014).","journal-title":"Int. J. Pharm."},{"key":"1467_CR280","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1039\/b400317a","volume":"14","author":"R Gonzalez-McQuire","year":"2004","unstructured":"Gonzalez-McQuire, R., Chane-Ching, J.-Y., Vignaud, E., Lebugle, A. & Mann, S. Synthesis and characterization of amino acid-functionalized hydroxyapatite nanorods. J. Mater. Chem. 14, 2277\u20132281 (2004).","journal-title":"J. Mater. Chem."},{"key":"1467_CR281","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/10611860108997922","volume":"9","author":"T Sekido","year":"2001","unstructured":"Sekido, T. et al. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J. Drug Target. 9, 111\u2013121 (2001).","journal-title":"J. Drug Target."},{"key":"1467_CR282","doi-asserted-by":"publisher","first-page":"25947","DOI":"10.1074\/jbc.M312314200","volume":"279","author":"JV Walker","year":"2004","unstructured":"Walker, J. V. et al. A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells. J. Biol. Chem. 279, 25947\u201325954 (2004).","journal-title":"J. Biol. Chem."},{"key":"1467_CR283","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jconrel.2020.09.047","volume":"329","author":"JJ Nielsen","year":"2021","unstructured":"Nielsen, J. J. et al. Analysis of the bone fracture targeting properties of osteotropic ligands. J. Control. Release 329, 570\u2013584 (2021).","journal-title":"J. Control. Release"},{"key":"1467_CR284","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1006\/jmbi.2001.4675","volume":"309","author":"HJ Snijder","year":"2001","unstructured":"Snijder, H. J. et al. Structural investigations of calcium binding and its role in activity and activation of outer membrane phospholipase A from Escherichia coli. J. Mol. Biol. 309, 477\u2013489 (2001).","journal-title":"J. Mol. Biol."},{"key":"1467_CR285","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/psc.941","volume":"14","author":"J Ruczy\u0144ski","year":"2008","unstructured":"Ruczy\u0144ski, J., Lewandowska, B., Mucha, P. & Rekowski, P. Problem of aspartimide formation in Fmoc-based solid-phase peptide synthesis using Dmab group to protect side chain of aspartic acid. J. Pept. Sci. 14, 335\u2013341 (2008).","journal-title":"J. Pept. Sci."},{"key":"1467_CR286","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.biomaterials.2015.02.007","volume":"52","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials 52, 148\u2013160 (2015).","journal-title":"Biomaterials"},{"key":"1467_CR287","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.2147\/IJN.S139775","volume":"12","author":"M Cai","year":"2017","unstructured":"Cai, M. et al. A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy. Int. J. Nanomed. 12, 7469\u20137482 (2017).","journal-title":"Int. J. Nanomed."},{"key":"1467_CR288","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biomaterials.2018.07.046","volume":"182","author":"L Huang","year":"2018","unstructured":"Huang, L. et al. A bone-targeting delivery system carrying osteogenic phytomolecule icaritin prevents osteoporosis in mice. Biomaterials 182, 58\u201371 (2018).","journal-title":"Biomaterials"},{"key":"1467_CR289","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bone.2017.09.011","volume":"106","author":"S Chen","year":"2018","unstructured":"Chen, S. et al. A novel bone targeting delivery system carrying phytomolecule icaritin for prevention of steroid-associated osteonecrosis in rats. Bone 106, 52\u201360 (2018).","journal-title":"Bone"},{"key":"1467_CR290","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s00198-015-3272-1","volume":"26","author":"ML Bianchi","year":"2015","unstructured":"Bianchi, M. L. Hypophosphatasia: an overview of the disease and its treatment. Osteoporos. Int. 26, 2743\u20132757 (2015).","journal-title":"Osteoporos. Int."},{"key":"1467_CR291","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/jbmr.3226","volume":"32","author":"JR Shapiro","year":"2017","unstructured":"Shapiro, J. R. & Lewiecki, E. M. Hypophosphatasia in adults: clinical assessment and treatment considerations. J. Bone Miner. Res. 32, 1977\u20131980 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR292","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1210\/jc.2006-1902","volume":"92","author":"MP Whyte","year":"2007","unstructured":"Whyte, M. P., Mumm, S. & Deal, C. Adult hypophosphatasia treated with teriparatide. J. Clin. Endocrinol. Metab. 92, 1203\u20131208 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1467_CR293","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1210\/jc.2009-1965","volume":"95","author":"C Gagnon","year":"2010","unstructured":"Gagnon, C. et al. Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J. Clin. Endocrinol. Metab. 95, 1007\u20131012 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1467_CR294","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte, M. P. et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N. Engl. J. Med. 366, 904\u2013913 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR295","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte, M. P. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 12, 233\u2013246 (2016).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1467_CR296","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40265-015-0535-2","volume":"76","author":"LJ Scott","year":"2016","unstructured":"Scott, L. J. Asfotase alfa: a review in paediatric-onset hypophosphatasia. Drugs 76, 255\u2013262 (2016).","journal-title":"Drugs"},{"key":"1467_CR297","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nm.2617","volume":"18","author":"G Zhang","year":"2012","unstructured":"Zhang, G. et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat. Med. 18, 307\u2013314 (2012).","journal-title":"Nat. Med."},{"key":"1467_CR298","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1021\/bc7002132","volume":"18","author":"D Wang","year":"2007","unstructured":"Wang, D. et al. Osteotropic peptide that differentiates functional domains of the skeleton. Bioconjug. Chem. 18, 1375\u20131378 (2007).","journal-title":"Bioconjug. Chem."},{"key":"1467_CR299","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s11095-008-9706-0","volume":"25","author":"SC Miller","year":"2008","unstructured":"Miller, S. C. et al. Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats. Pharm. Res. 25, 2889\u20132895 (2008).","journal-title":"Pharm. Res."},{"key":"1467_CR300","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1021\/bm070121s","volume":"8","author":"MB Murphy","year":"2007","unstructured":"Murphy, M. B., Hartgerink, J. D., Goepferich, A. & Mikos, A. G. Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties. Biomacromolecules 8, 2237\u20132243 (2007).","journal-title":"Biomacromolecules"},{"key":"1467_CR301","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/med.21759","volume":"41","author":"F Ordikhani","year":"2021","unstructured":"Ordikhani, F. et al. Targeted nanomedicines for the treatment of bone disease and regeneration. Med. Res. Rev. 41, 1221\u20131254 (2021).","journal-title":"Med. Res. Rev."},{"key":"1467_CR302","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1096\/fj.14-269092","volume":"29","author":"CN Mattar","year":"2015","unstructured":"Mattar, C. N. et al. Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates. FASEB J. 29, 3876\u20133888 (2015).","journal-title":"FASEB J."},{"key":"1467_CR303","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33956-9","volume":"13","author":"Y-S Yang","year":"2022","unstructured":"Yang, Y.-S. et al. Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Nat. Commun. 13, 6175 (2022).","journal-title":"Nat. Commun."},{"key":"1467_CR304","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00198-005-2035-9","volume":"17","author":"S Viguet-Carrin","year":"2006","unstructured":"Viguet-Carrin, S., Garnero, P. & Delmas, P. D. The role of collagen in bone strength. Osteoporos. Int. 17, 319\u2013336 (2006).","journal-title":"Osteoporos. Int."},{"key":"1467_CR305","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s00253-003-1442-0","volume":"63","author":"K Watanabe","year":"2004","unstructured":"Watanabe, K. Collagenolytic proteases from bacteria. Appl. Microbiol. Biotechnol. 63, 520\u2013526 (2004).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"1467_CR306","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00223-011-9485-1","volume":"88","author":"T Ponnapakkam","year":"2011","unstructured":"Ponnapakkam, T. et al. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice. Calcif. Tissue Int. 88, 511\u2013520 (2011).","journal-title":"Calcif. Tissue Int."},{"key":"1467_CR307","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00223-012-9626-1","volume":"91","author":"T Ponnapakkam","year":"2012","unstructured":"Ponnapakkam, T. et al. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice. Calcif. Tissue Int. 91, 196\u2013203 (2012).","journal-title":"Calcif. Tissue Int."},{"key":"1467_CR308","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0169-409X(97)00119-1","volume":"31","author":"A Sano","year":"1998","unstructured":"Sano, A., Hojo, T., Maeda, M. & Fujioka, K. Protein release from collagen matrices. Adv. Drug Deliv. Rev. 31, 247\u2013266 (1998).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1467_CR309","doi-asserted-by":"crossref","unstructured":"Katikaneni, R. et al. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int. J. Cancer 131, E813\u2013E821 (2012).","DOI":"10.1002\/ijc.27379"},{"key":"1467_CR310","first-page":"513","volume":"128","author":"J Foley","year":"2001","unstructured":"Foley, J. et al. Parathyroid hormone-related protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development. Dev. Camb. Engl. 128, 513\u2013525 (2001).","journal-title":"Dev. Camb. Engl."},{"key":"1467_CR311","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.actbio.2021.03.011","volume":"126","author":"Y Tang","year":"2021","unstructured":"Tang, Y. et al. Laminin alpha 4 promotes bone regeneration by facilitating cell adhesion and vascularization. Acta Biomater. 126, 183\u2013198 (2021).","journal-title":"Acta Biomater."},{"key":"1467_CR312","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.bioactmat.2021.01.017","volume":"6","author":"S Xue","year":"2021","unstructured":"Xue, S. et al. Cartilage-targeting peptide-modified dual-drug delivery nanoplatform with NIR laser response for osteoarthritis therapy. Bioact. Mater. 6, 2372\u20132389 (2021).","journal-title":"Bioact. Mater."},{"key":"1467_CR313","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbrc.2014.08.055","volume":"452","author":"F Haasters","year":"2014","unstructured":"Haasters, F. et al. Mesenchymal stem cells from osteoporotic patients reveal reduced migration and invasion upon stimulation with BMP-2 or BMP-7. Biochem. Biophys. Res. Commun. 452, 118\u2013123 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1467_CR314","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jcyt.2020.12.005","volume":"23","author":"Q Pan","year":"2021","unstructured":"Pan, Q. et al. Local administration of allogeneic or autologous bone marrow-derived mesenchymal stromal cells enhances bone formation similarly in distraction osteogenesis. Cytotherapy 23, 590\u2013598 (2021).","journal-title":"Cytotherapy"},{"key":"1467_CR315","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bjoms.2009.06.226","volume":"48","author":"R Gutwald","year":"2010","unstructured":"Gutwald, R. et al. Mesenchymal stem cells and inorganic bovine bone mineral in sinus augmentation: comparison with augmentation by autologous bone in adult sheep. Br. J. Oral. Maxillofac. Surg. 48, 285\u2013290 (2010).","journal-title":"Br. J. Oral. Maxillofac. Surg."},{"key":"1467_CR316","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.moh.0000177827.78280.79","volume":"12","author":"R Sackstein","year":"2005","unstructured":"Sackstein, R. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr. Opin. Hematol. 12, 444\u2013450 (2005).","journal-title":"Curr. Opin. Hematol."},{"key":"1467_CR317","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nm1703","volume":"14","author":"R Sackstein","year":"2008","unstructured":"Sackstein, R. et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14, 181\u2013187 (2008).","journal-title":"Nat. Med."},{"key":"1467_CR318","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.yexcr.2016.11.010","volume":"350","author":"K-J Chou","year":"2017","unstructured":"Chou, K.-J. et al. CD44 fucosylation on mesenchymal stem cell enhances homing and macrophage polarization in ischemic kidney injury. Exp. Cell Res. 350, 91\u2013102 (2017).","journal-title":"Exp. Cell Res."},{"key":"1467_CR319","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.exphem.2011.03.004","volume":"39","author":"S Bobis-Wozowicz","year":"2011","unstructured":"Bobis-Wozowicz, S. et al. Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD\/SCID mice. Exp. Hematol. 39, 686\u2013696.e4 (2011).","journal-title":"Exp. Hematol."},{"key":"1467_CR320","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/cmi.2017.107","volume":"15","author":"R Janssens","year":"2018","unstructured":"Janssens, R., Struyf, S. & Proost, P. The unique structural and functional features of CXCL12. Cell. Mol. Immunol. 15, 299\u2013311 (2018).","journal-title":"Cell. Mol. Immunol."},{"key":"1467_CR321","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jor.22749","volume":"33","author":"S Herberg","year":"2015","unstructured":"Herberg, S. et al. Mesenchymal stem cell expression of stromal cell-derived factor-1\u03b2 augments bone formation in a model of local regenerative therapy. J. Orthop. Res. 33, 174\u2013184 (2015).","journal-title":"J. Orthop. Res."},{"key":"1467_CR322","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1096\/fj.07-8275com","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar, S. & Ponnazhagan, S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. FASEB J. 21, 3917\u20133927 (2007).","journal-title":"FASEB J."},{"key":"1467_CR323","doi-asserted-by":"crossref","unstructured":"Chen, Q. et al. Bone targeted delivery of SDF-1 via alendronate functionalized nanoparticles in guiding stem cell migration. ACS Appl. Mater. Interfaces 10, 23700\u201323710 (2018).","DOI":"10.1021\/acsami.8b08606"},{"key":"1467_CR324","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jcp.10445","volume":"199","author":"F Grassi","year":"2004","unstructured":"Grassi, F. et al. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J. Cell. Physiol. 199, 244\u2013251 (2004).","journal-title":"J. Cell. Physiol."},{"key":"1467_CR325","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tem.2007.02.002","volume":"18","author":"S Gronthos","year":"2007","unstructured":"Gronthos, S. & Zannettino, A. C. W. The role of the chemokine CXCL12 in osteoclastogenesis. Trends Endocrinol. Metab. 18, 108\u2013113 (2007).","journal-title":"Trends Endocrinol. Metab."},{"key":"1467_CR326","doi-asserted-by":"crossref","unstructured":"Im, J. Y. et al. AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem\/progenitor cells. BMB Rep. 47, 439\u2013444 (2014).","DOI":"10.5483\/BMBRep.2014.47.8.159"},{"key":"1467_CR327","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.exphem.2014.07.261","volume":"42","author":"MK Pandey","year":"2014","unstructured":"Pandey, M. K. et al. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Exp. Hematol. 42, 883\u2013896 (2014).","journal-title":"Exp. Hematol."},{"key":"1467_CR328","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/jbmr.4002","volume":"35","author":"F Ponte","year":"2020","unstructured":"Ponte, F. et al. Cxcl12 deletion in mesenchymal cells increases bone turnover and attenuates the loss of cortical bone caused by estrogen deficiency in mice. J. Bone Miner. Res. 35, 1441\u20131451 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR329","doi-asserted-by":"crossref","unstructured":"Zhang, C. et al. Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy. J. Nanobiotechnol. 20, 35 (2022).","DOI":"10.1186\/s12951-021-01231-6"},{"key":"1467_CR330","doi-asserted-by":"publisher","first-page":"E1852","DOI":"10.3390\/ijms18091852","volume":"18","author":"FJ Vizoso","year":"2017","unstructured":"Vizoso, F. J., Eiro, N., Cid, S., Schneider, J. & Perez-Fernandez, R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int. J. Mol. Sci. 18, E1852 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"1467_CR331","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1634\/stemcells.2005-0319","volume":"24","author":"M Honczarenko","year":"2006","unstructured":"Honczarenko, M. et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24, 1030\u20131041 (2006).","journal-title":"Stem Cells"},{"key":"1467_CR332","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1634\/stemcells.22-6-1030","volume":"22","author":"GS Nowakowski","year":"2004","unstructured":"Nowakowski, G. S. et al. A specific heptapeptide from a phage display peptide library homes to bone marrow and binds to primitive hematopoietic stem cells. Stem Cells 22, 1030\u20131038 (2004).","journal-title":"Stem Cells"},{"key":"1467_CR333","doi-asserted-by":"publisher","first-page":"eabk0011","DOI":"10.1126\/sciadv.abk0011","volume":"8","author":"J Zhu","year":"2022","unstructured":"Zhu, J. et al. Stem cell-homing hydrogel-based miR-29b-5p delivery promotes cartilage regeneration by suppressing senescence in an osteoarthritis rat model. Sci. Adv. 8, eabk0011 (2022).","journal-title":"Sci. Adv."},{"key":"1467_CR334","first-page":"326","volume":"42","author":"R Haubner","year":"2001","unstructured":"Haubner, R. et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326\u2013336 (2001).","journal-title":"J. Nucl. Med."},{"key":"1467_CR335","first-page":"311","volume":"48","author":"JE Sprague","year":"2007","unstructured":"Sprague, J. E. et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J. Nucl. Med. 48, 311\u2013318 (2007).","journal-title":"J. Nucl. Med."},{"key":"1467_CR336","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang, J., Nakamura, H. & Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136\u2013151 (2011).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1467_CR337","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jconrel.2014.10.012","volume":"196","author":"F Wang","year":"2014","unstructured":"Wang, F., Chen, L., Zhang, R., Chen, Z. & Zhu, L. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J. Control. Release 196, 222\u2013233 (2014).","journal-title":"J. Control. Release"},{"key":"1467_CR338","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.2147\/IJN.S109966","volume":"11","author":"DDS Ferreira","year":"2016","unstructured":"Ferreira, D. D. S. et al. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis. Int. J. Nanomed. 11, 3737\u20133751 (2016).","journal-title":"Int. J. Nanomed."},{"key":"1467_CR339","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1016\/j.bmcl.2012.05.105","volume":"22","author":"SMZMD Ferreira","year":"2012","unstructured":"Ferreira, S. M. Z. M. D. et al. Technetium-99m-labeled ceftizoxime loaded long-circulating and pH-sensitive liposomes used to identify osteomyelitis. Bioorg. Med. Chem. Lett. 22, 4605\u20134608 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1467_CR340","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.bioactmat.2021.04.038","volume":"6","author":"C Dou","year":"2021","unstructured":"Dou, C. et al. Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis. Bioact. Mater. 6, 4697\u20134706 (2021).","journal-title":"Bioact. Mater."},{"key":"1467_CR341","doi-asserted-by":"crossref","unstructured":"Granholm, S., Henning, P. & Lerner, U. H. Comparisons between the effects of calcitonin receptor-stimulating peptide and intermedin and other peptides in the calcitonin family on bone resorption and osteoclastogenesis. J. Cell. Biochem. 112, 3300\u20133312 (2011).","DOI":"10.1002\/jcb.23256"},{"key":"1467_CR342","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00223-009-9309-8","volume":"85","author":"AJ Janckila","year":"2009","unstructured":"Janckila, A. J. & Yam, L. T. Biology and clinical significance of tartrate-resistant acid phosphatases: new perspectives on an old enzyme. Calcif. Tissue Int. 85, 465\u2013483 (2009).","journal-title":"Calcif. Tissue Int."},{"key":"1467_CR343","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1039\/D2BM00076H","volume":"10","author":"B Zhang","year":"2022","unstructured":"Zhang, B. et al. A novel nano delivery system targeting different stages of osteoclasts. Biomater. Sci. 10, 1821\u20131830 (2022).","journal-title":"Biomater. Sci."},{"key":"1467_CR344","doi-asserted-by":"publisher","first-page":"e1706759","DOI":"10.1002\/adma.201706759","volume":"30","author":"RH Fang","year":"2018","unstructured":"Fang, R. H., Kroll, A. V., Gao, W. & Zhang, L. Cell membrane coating nanotechnology. Adv. Mater. 30, e1706759 (2018).","journal-title":"Adv. Mater."},{"key":"1467_CR345","doi-asserted-by":"publisher","first-page":"eabn3333","DOI":"10.1126\/sciadv.abn3333","volume":"8","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Suppression of osteoclast multinucleation via a posttranscriptional regulation-based spatiotemporally selective delivery system. Sci. Adv. 8, eabn3333 (2022).","journal-title":"Sci. Adv."},{"key":"1467_CR346","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1021\/acsnano.5b07828","volume":"10","author":"Y Sun","year":"2016","unstructured":"Sun, Y. et al. Osteoblast-targeting-peptide modified nanoparticle for siRNA\/microRNA delivery. ACS Nano 10, 5759\u20135768 (2016).","journal-title":"ACS Nano"},{"key":"1467_CR347","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bioactmat.2021.09.015","volume":"10","author":"Y Cui","year":"2022","unstructured":"Cui, Y. et al. A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact. Mater. 10, 207\u2013221 (2022).","journal-title":"Bioact. Mater."},{"key":"1467_CR348","doi-asserted-by":"publisher","first-page":"20884","DOI":"10.1039\/C9NR02791B","volume":"11","author":"Z-W Luo","year":"2019","unstructured":"Luo, Z.-W. et al. Aptamer-functionalized exosomes from bone marrow stromal cells target bone to promote bone regeneration. Nanoscale 11, 20884\u201320892 (2019).","journal-title":"Nanoscale"},{"key":"1467_CR349","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1016\/j.biomaterials.2012.01.033","volume":"33","author":"Z Shao","year":"2012","unstructured":"Shao, Z. et al. Polycaprolactone electrospun mesh conjugated with an MSC affinity peptide for MSC homing in vivo. Biomaterials 33, 3375\u20133387 (2012).","journal-title":"Biomaterials"},{"key":"1467_CR350","doi-asserted-by":"publisher","first-page":"120539","DOI":"10.1016\/j.biomaterials.2020.120539","volume":"269","author":"X Xu","year":"2021","unstructured":"Xu, X. et al. Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials 269, 120539 (2021).","journal-title":"Biomaterials"},{"key":"1467_CR351","doi-asserted-by":"publisher","first-page":"121474","DOI":"10.1016\/j.biomaterials.2022.121474","volume":"283","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. Highly effective rheumatoid arthritis therapy by peptide-promoted nanomodification of mesenchymal stem cells. Biomaterials 283, 121474 (2022).","journal-title":"Biomaterials"},{"key":"1467_CR352","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/adfm.201102963","volume":"23","author":"K Ma","year":"2013","unstructured":"Ma, K. et al. Synergetic targeted delivery of sleeping-beauty transposon system to mesenchymal stem cells using LPD nanoparticles modified with a phage-displayed targeting peptide. Adv. Funct. Mater. 23, 1172\u20131181 (2013).","journal-title":"Adv. Funct. Mater."},{"key":"1467_CR353","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","volume":"194","author":"NE Lane","year":"2006","unstructured":"Lane, N. E. Epidemiology, etiology, and diagnosis of osteoporosis. Am. J. Obstet. Gynecol. 194, S3\u2013S11 (2006).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1467_CR354","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1056\/NEJMoa0802633","volume":"360","author":"RS Weinstein","year":"2009","unstructured":"Weinstein, R. S., Roberson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53\u201362 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR355","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid, I. R. et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Miner. Res. 25, 2256\u20132265 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR356","first-page":"669","volume":"15","author":"A Mullard","year":"2016","unstructured":"Mullard, A. Merck &Co. drops osteoporosis drug odanacatib. Nat. Rev. Drug Discov. 15, 669 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1467_CR357","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrd2780","volume":"8","author":"AS Verkman","year":"2009","unstructured":"Verkman, A. S. & Galietta, L. J. V. Chloride channels as drug targets. Nat. Rev. Drug Discov. 8, 153\u2013171 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1467_CR358","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1359\/JBMR.040302","volume":"19","author":"S Schaller","year":"2004","unstructured":"Schaller, S. et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J. Bone Miner. Res. 19, 1144\u20131153 (2004).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR359","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0092-8674(01)00206-9","volume":"104","author":"U Kornak","year":"2001","unstructured":"Kornak, U. et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104, 205\u2013215 (2001).","journal-title":"Cell"},{"key":"1467_CR360","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nm842","volume":"9","author":"N Chalhoub","year":"2003","unstructured":"Chalhoub, N. et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat. Med. 9, 399\u2013406 (2003).","journal-title":"Nat. Med."},{"key":"1467_CR361","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1172\/JCI119404","volume":"99","author":"VW Engleman","year":"1997","unstructured":"Engleman, V. W. et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 99, 2284\u20132292 (1997).","journal-title":"J. Clin. Invest."},{"key":"1467_CR362","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1083\/jcb.201410123","volume":"208","author":"W Zou","year":"2014","unstructured":"Zou, W. & Teitelbaum, S. L. Absence of Dap12 and the \u03b1v\u03b23 integrin causes severe osteopetrosis. J. Cell Biol. 208, 125\u2013136 (2014).","journal-title":"J. Cell Biol."},{"key":"1467_CR363","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1210\/jc.2004-2126","volume":"90","author":"MG Murphy","year":"2005","unstructured":"Murphy, M. G. et al. Effect of L-000845704, an \u03b1V\u03b23 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 90, 2022\u20132028 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1467_CR364","doi-asserted-by":"crossref","unstructured":"Burden, A. M. & Weiler, S. Association between osteoporosis and statins therapy: the story continues. Ann. Rheum. Dis. 80, e204 (2021).","DOI":"10.1136\/annrheumdis-2019-216574"},{"key":"1467_CR365","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrendo.2013.4","volume":"9","author":"PJ Marie","year":"2013","unstructured":"Marie, P. J. Targeting integrins to promote bone formation and repair. Nat. Rev. Endocrinol. 9, 288\u2013295 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1467_CR366","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.5966\/sctm.2015-0347","volume":"5","author":"B Sui","year":"2016","unstructured":"Sui, B. et al. Allogeneic mesenchymal stem cell therapy promotes osteoblastogenesis and prevents glucocorticoid-induced osteoporosis. Stem Cells Transl. Med. 5, 1238\u20131246 (2016).","journal-title":"Stem Cells Transl. Med."},{"key":"1467_CR367","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/0022034517706070","volume":"96","author":"Y Yin","year":"2017","unstructured":"Yin, Y. et al. Leveraging stem cell homing for therapeutic regeneration. J. Dent. Res. 96, 601\u2013609 (2017).","journal-title":"J. Dent. Res."},{"key":"1467_CR368","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11914-019-00504-2","volume":"17","author":"RJ Pignolo","year":"2019","unstructured":"Pignolo, R. J., Samsonraj, R. M., Law, S. F., Wang, H. & Chandra, A. Targeting cell senescence for the treatment of age-related bone loss. Curr. Osteoporos. Rep. 17, 70\u201385 (2019).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1467_CR369","doi-asserted-by":"publisher","first-page":"e90220","DOI":"10.1172\/jci.insight.90220","volume":"1","author":"J-S Yi","year":"2016","unstructured":"Yi, J.-S. et al. Low-dose dasatinib rescues cardiac function in Noonan syndrome. JCI Insight 1, e90220 (2016).","journal-title":"JCI Insight"},{"key":"1467_CR370","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.fitote.2015.09.018","volume":"106","author":"G D\u2019Andrea","year":"2015","unstructured":"D\u2019Andrea, G. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia 106, 256\u2013271 (2015).","journal-title":"Fitoterapia"},{"key":"1467_CR371","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jnutbio.2013.11.003","volume":"25","author":"Y-H Kim","year":"2014","unstructured":"Kim, Y.-H. et al. Fisetin antagonizes cell fusion, cytoskeletal organization and bone resorption in RANKL-differentiated murine macrophages. J. Nutr. Biochem. 25, 295\u2013303 (2014).","journal-title":"J. Nutr. Biochem."},{"key":"1467_CR372","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25453-2","volume":"12","author":"EJ Novais","year":"2021","unstructured":"Novais, E. J. et al. Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat. Commun. 12, 5213 (2021).","journal-title":"Nat. Commun."},{"key":"1467_CR373","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41584-020-00533-7","volume":"17","author":"PR Coryell","year":"2021","unstructured":"Coryell, P. R., Diekman, B. O. & Loeser, R. F. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat. Rev. Rheumatol. 17, 47\u201357 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1467_CR374","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nm.4385","volume":"23","author":"JN Farr","year":"2017","unstructured":"Farr, J. N. et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat. Med. 23, 1072\u20131079 (2017).","journal-title":"Nat. Med."},{"key":"1467_CR375","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson, L. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446\u2013456 (2019).","journal-title":"EBioMedicine"},{"key":"1467_CR376","unstructured":"Howlader, N. et al (eds). SEER Cancer Statistics Review, 1975-2018 (National Cancer Institute, 2021)."},{"key":"1467_CR377","doi-asserted-by":"publisher","first-page":"e15582","DOI":"10.1097\/MD.0000000000015582","volume":"98","author":"D Yu","year":"2019","unstructured":"Yu, D. et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation. Medicine 98, e15582 (2019).","journal-title":"Medicine"},{"key":"1467_CR378","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du, Z. & Lovly, C. M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 17, 58 (2018).","journal-title":"Mol. Cancer"},{"key":"1467_CR379","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill, J. & Gorlick, R. Advancing therapy for osteosarcoma. Nat. Rev. Clin. Oncol. 18, 609\u2013624 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1467_CR380","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1051\/sicotj\/2017028","volume":"4","author":"A Misaghi","year":"2018","unstructured":"Misaghi, A., Goldin, A., Awad, M. & Kulidjian, A. A. Osteosarcoma: a comprehensive review. SICOT J. 4, 12 (2018).","journal-title":"SICOT J."},{"key":"1467_CR381","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/jbmr.2182","volume":"29","author":"T Ohba","year":"2014","unstructured":"Ohba, T. et al. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. J. Bone Miner. Res. 29, 1431\u20131445 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR382","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/0008-5472.CAN-09-4291","volume":"70","author":"L Endo-Munoz","year":"2010","unstructured":"Endo-Munoz, L. et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 70, 7063\u20137072 (2010).","journal-title":"Cancer Res."},{"key":"1467_CR383","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","volume":"17","author":"S Piperno-Neumann","year":"2016","unstructured":"Piperno-Neumann, S. et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 17, 1070\u20131080 (2016).","journal-title":"Lancet Oncol."},{"key":"1467_CR384","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-018-0036-5","volume":"7","author":"Y Nakai","year":"2019","unstructured":"Nakai, Y. et al. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 7, 1 (2019).","journal-title":"Bone Res."},{"key":"1467_CR385","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.cr.7290266","volume":"15","author":"JJ Yin","year":"2005","unstructured":"Yin, J. J., Pollock, C. B. & Kelly, K. Mechanisms of cancer metastasis to the bone. Cell Res. 15, 57\u201362 (2005).","journal-title":"Cell Res."},{"key":"1467_CR386","first-page":"98","volume":"8","author":"S Paget","year":"1989","unstructured":"Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98\u2013101 (1989).","journal-title":"Cancer Metastasis Rev."},{"key":"1467_CR387","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00520-017-3583-1","volume":"25","author":"Y Qian","year":"2017","unstructured":"Qian, Y., Bhowmik, D., Kachru, N. & Hernandez, R. K. Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Support. Care Cancer 25, 1845\u20131851 (2017).","journal-title":"Support. Care Cancer"},{"key":"1467_CR388","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132\u20135139 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1467_CR389","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet Lond. Engl. 377, 813\u2013822 (2011).","journal-title":"Lancet Lond. Engl."},{"key":"1467_CR390","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125\u20131132 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1467_CR391","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith, M. R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet Lond. Engl. 379, 39\u201346 (2012).","journal-title":"Lancet Lond. Engl."},{"key":"1467_CR392","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s12032-014-0898-3","volume":"31","author":"Z Song","year":"2014","unstructured":"Song, Z. & Zhang, Y. Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. Med. Oncol. 31, 898 (2014).","journal-title":"Med. Oncol."},{"key":"1467_CR393","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20138-8","volume":"11","author":"C G\u00f3mez-Aleza","year":"2020","unstructured":"G\u00f3mez-Aleza, C. et al. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nat. Commun. 11, 6335 (2020).","journal-title":"Nat. Commun."},{"key":"1467_CR394","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/1078-0432.CCR-18-2482","volume":"25","author":"TD Rachner","year":"2019","unstructured":"Rachner, T. D. et al. Prognostic value of RANKL\/OPG serum levels and disseminated tumor cells in nonmetastatic breast cancer. Clin. Cancer Res. 25, 1369\u20131378 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1467_CR395","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jbspin.2011.04.013","volume":"78","author":"S Saidi","year":"2011","unstructured":"Saidi, S. & Magne, D. Interleukin-33: A novel player in osteonecrosis of the femoral head? Jt. Bone Spine 78, 550\u2013554 (2011).","journal-title":"Jt. Bone Spine"},{"key":"1467_CR396","first-page":"132","volume":"27","author":"J Zhao","year":"2021","unstructured":"Zhao, J. et al. Local administration of zoledronic acid prevents traumatic osteonecrosis of the femoral head in rat model. J. Orthop. Transl. 27, 132\u2013138 (2021).","journal-title":"J. Orthop. Transl."},{"key":"1467_CR397","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1359\/jbmr.2003.18.11.2016","volume":"18","author":"DG Little","year":"2003","unstructured":"Little, D. G. et al. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J. Bone Miner. Res. 18, 2016\u20132022 (2003).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR398","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00402-012-1617-1","volume":"132","author":"C Bartl","year":"2012","unstructured":"Bartl, C., Imhoff, A. & Bartl, R. Treatment of bone marrow edema syndrome with intravenous Ibandronate. Arch. Orthop. Trauma Surg. 132, 1781\u20131788 (2012).","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"1467_CR399","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2106\/JBJS.N.01157","volume":"97","author":"Y-K Lee","year":"2015","unstructured":"Lee, Y.-K. et al. Does zoledronate prevent femoral head collapse from osteonecrosis? A prospective, randomized, open-label, multicenter study. J. Bone Jt. Surg. Am. 97, 1142\u20131148 (2015).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"1467_CR400","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","volume":"48","author":"S K\u00fchl","year":"2012","unstructured":"K\u00fchl, S., Walter, C., Acham, S., Pfeffer, R. & Lambrecht, J. T. Bisphosphonate-related osteonecrosis of the jaws\u2013a review. Oral. Oncol. 48, 938\u2013947 (2012).","journal-title":"Oral. Oncol."},{"key":"1467_CR401","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cca.2022.02.009","volume":"529","author":"S-W Zheng","year":"2022","unstructured":"Zheng, S.-W. et al. Decreased serum CXCL12\/SDF-1 concentrations may reflect disease severity of non-traumatic osteonecrosis of femoral head. Clin. Chim. Acta 529, 87\u201395 (2022).","journal-title":"Clin. Chim. Acta"},{"key":"1467_CR402","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-020-00864-8","volume":"13","author":"X Li","year":"2020","unstructured":"Li, X. et al. Mechanisms and rejuvenation strategies for aged hematopoietic stem cells. J. Hematol. Oncol. J. Hematol. Oncol. 13, 31 (2020).","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"1467_CR403","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cell.2005.12.023","volume":"124","author":"C Ruiz de Almodovar","year":"2006","unstructured":"Ruiz de Almodovar, C., Luttun, A. & Carmeliet, P. An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell 124, 18\u201321 (2006).","journal-title":"Cell"},{"key":"1467_CR404","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/jcm10030508","volume":"10","author":"E G\u00f3mez-Barrena","year":"2021","unstructured":"G\u00f3mez-Barrena, E. et al. Osteonecrosis of the femoral head safely healed with autologous, expanded, bone marrow-derived mesenchymal stromal cells in a multicentric trial with minimum 5 years follow-up. J. Clin. Med. 10, 508 (2021).","journal-title":"J. Clin. Med."},{"key":"1467_CR405","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jcyt.2015.02.002","volume":"17","author":"J Vives","year":"2015","unstructured":"Vives, J., Oliver-Vila, I. & Pla, A. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy 17, 1009\u20131014 (2015).","journal-title":"Cytotherapy"},{"key":"1467_CR406","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/1440-1681.13441","volume":"48","author":"M Jiang","year":"2021","unstructured":"Jiang, M. et al. An MSC bone-homing compound, Rab001, increases bone mass and reduces the incidence of osteonecrosis in a glucocorticoid-induced osteonecrosis mouse model. Clin. Exp. Pharmacol. Physiol. 48, 770\u2013781 (2021).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"1467_CR407","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.metabol.2017.06.010","volume":"80","author":"T Cundy","year":"2018","unstructured":"Cundy, T. Paget\u2019s disease of bone. Metabolism 80, 5\u201314 (2018).","journal-title":"Metabolism"},{"key":"1467_CR408","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/095952877706000105","volume":"60","author":"J Paget","year":"1877","unstructured":"Paget, J. On a form of chronic inflammation of bones (Osteitis Deformans). Med. Chir. Trans. 60, 37\u201364.9 (1877).","journal-title":"Med. Chir. Trans."},{"key":"1467_CR409","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrendo.2015.138","volume":"11","author":"FR Singer","year":"2015","unstructured":"Singer, F. R. Paget\u2019s disease of bone-genetic and environmental factors. Nat. Rev. Endocrinol. 11, 662\u2013671 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1467_CR410","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1023\/A:1010010912302","volume":"2","author":"SV Reddy","year":"2001","unstructured":"Reddy, S. V., Kurihara, N., Menaa, C. & Roodman, G. D. Paget\u2019s disease of bone: a disease of the osteoclast. Rev. Endocr. Metab. Disord. 2, 195\u2013201 (2001).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"1467_CR411","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4158\/EP.11.6.399","volume":"11","author":"S Gupta","year":"2005","unstructured":"Gupta, S. & Cheikh, I. E. Camurati-Engelmann disease in conjunction with hypogonadism. Endocr. Pract. 11, 399\u2013407 (2005).","journal-title":"Endocr. Pract."},{"key":"1467_CR412","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1091\/mbc.9.7.1903","volume":"9","author":"A Erlebacher","year":"1998","unstructured":"Erlebacher, A., Filvaroff, E. H., Ye, J. Q. & Derynck, R. Osteoblastic responses to TGF-beta during bone remodeling. Mol. Biol. Cell 9, 1903\u20131918 (1998).","journal-title":"Mol. Biol. Cell"},{"key":"1467_CR413","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nm.1979","volume":"15","author":"Y Tang","year":"2009","unstructured":"Tang, Y. et al. TGF-\u03b21\u2013induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757\u2013765 (2009).","journal-title":"Nat. Med."},{"key":"1467_CR414","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0006-291X(89)92795-2","volume":"158","author":"ROC Oreffo","year":"1989","unstructured":"Oreffo, R. O. C., Mundy, G. R., Seyedin, S. M. & Bonewald, L. F. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem. Biophys. Res. Commun. 158, 817\u2013823 (1989).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1467_CR415","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0140-6736(68)90236-5","volume":"1","author":"OL Bijvoet","year":"1968","unstructured":"Bijvoet, O. L., van der Sluys Veer, J. & Jansen, A. P. Effects of calcitonin on patients with Paget\u2019s disease, thyrotoxicosis, or hypercalcaemia. Lancet Lond. Engl. 1, 876\u2013881 (1968).","journal-title":"Lancet Lond. Engl."},{"key":"1467_CR416","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJM197312272892601","volume":"289","author":"RD Altman","year":"1973","unstructured":"Altman, R. D. et al. Influence of disodium etidronate on clinical and laboratory manifestations of Paget\u2019s disease of bone (osteitis deformans). N. Engl. J. Med. 289, 1379\u20131384 (1973).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR417","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid, I. R. et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N. Engl. J. Med. 353, 898\u2013908 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR418","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/jbmr.3029","volume":"32","author":"T Cundy","year":"2017","unstructured":"Cundy, T., Maslowski, K., Grey, A. & Reid, I. R. Durability of response to zoledronate treatment and competing mortality in Paget\u2019s disease of bone. J. Bone Miner. Res. 32, 753\u2013756 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR419","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fcell.2015.00051","volume":"3","author":"SV Komarova","year":"2015","unstructured":"Komarova, S. V. et al. Mathematical model for bone mineralization. Front. Cell Dev. Biol. 3, 51 (2015).","journal-title":"Front. Cell Dev. Biol."},{"key":"1467_CR420","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00198-016-3709-1","volume":"27","author":"G Bardai","year":"2016","unstructured":"Bardai, G., Moffatt, P., Glorieux, F. H. & Rauch, F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteoporos. Int. 27, 3607\u20133613 (2016).","journal-title":"Osteoporos. Int."},{"key":"1467_CR421","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/ajmg.a.61366","volume":"179","author":"GR Mortier","year":"2019","unstructured":"Mortier, G. R. et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am. J. Med. Genet. A. 179, 2393\u20132419 (2019).","journal-title":"Am. J. Med. Genet. A."},{"key":"1467_CR422","first-page":"e10118","volume":"3","author":"JS Bains","year":"2019","unstructured":"Bains, J. S. et al. A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta. JBMR 3, e10118 (2019).","journal-title":"JBMR"},{"key":"1467_CR423","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajmg.c.31532","volume":"172","author":"R Marom","year":"2016","unstructured":"Marom, R., Lee, Y.-C., Grafe, I. & Lee, B. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. Am. J. Med. Genet. C. Semin. Med. Genet. 172, 367\u2013383 (2016).","journal-title":"Am. J. Med. Genet. C. Semin. Med. Genet."},{"key":"1467_CR424","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1197-z","volume":"14","author":"H Hoyer-Kuhn","year":"2019","unstructured":"Hoyer-Kuhn, H., Rehberg, M., Netzer, C., Schoenau, E. & Semler, O. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort. Orphanet J. Rare Dis. 14, 219 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"1467_CR425","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn, H. et al. Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial. J. Musculoskelet. Neuronal Interact. 16, 24\u201332 (2016).","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"1467_CR426","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo, P., Rauch, F. & Ward, L. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J. Musculoskelet. Neuronal Interact. 18, 76\u201380 (2018).","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"1467_CR427","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll, E. S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J. Clin. Invest. 124, 491\u2013498 (2014).","journal-title":"J. Clin. Invest."},{"key":"1467_CR428","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/endrev\/bnab017","volume":"43","author":"M Jovanovic","year":"2022","unstructured":"Jovanovic, M., Guterman-Ram, G. & Marini, J. C. Osteogenesis imperfecta: mechanisms and signaling pathways connecting classical and rare OI types. Endocr. Rev. 43, 61\u201390 (2022).","journal-title":"Endocr. Rev."},{"key":"1467_CR429","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jbmr.1717","volume":"28","author":"BP Sinder","year":"2013","unstructured":"Sinder, B. P. et al. Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta. J. Bone Miner. Res. 28, 73\u201380 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR430","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/jbmr.2198","volume":"29","author":"CM Jacobsen","year":"2014","unstructured":"Jacobsen, C. M. et al. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J. Bone Miner. Res. 29, 2297\u20132306 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR431","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","volume":"20","author":"I Grafe","year":"2014","unstructured":"Grafe, I. et al. Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta. Nat. Med. 20, 670\u2013675 (2014).","journal-title":"Nat. Med."},{"key":"1467_CR432","unstructured":"Song, I.-W. et al. Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta. J. Clin. Invest. 132, e152571 (2022)."},{"key":"1467_CR433","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.matbio.2018.05.005","volume":"71\u201372","author":"Y Krishnan","year":"2018","unstructured":"Krishnan, Y. & Grodzinsky, A. J. Cartilage diseases. Matrix Biol. 71\u201372, 51\u201369 (2018).","journal-title":"Matrix Biol."},{"key":"1467_CR434","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal, L., Lwin, M. N., Holroyd, C. & Edwards, C. J. Rheumatoid arthritis in the elderly: characteristics and treatment considerations. Autoimmun. Rev. 19, 102528 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1467_CR435","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.joca.2014.07.015","volume":"22","author":"A Turkiewicz","year":"2014","unstructured":"Turkiewicz, A. et al. Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. Osteoarthr. Cartil. 22, 1826\u20131832 (2014).","journal-title":"Osteoarthr. Cartil."},{"key":"1467_CR436","doi-asserted-by":"publisher","first-page":"6090","DOI":"10.1002\/jcp.30313","volume":"236","author":"L Liu","year":"2021","unstructured":"Liu, L., Yuan, Y., Zhang, S., Xu, J. & Zou, J. Osteoimmunological insights into the pathogenesis of ankylosing spondylitis. J. Cell. Physiol. 236, 6090\u20136100 (2021).","journal-title":"J. Cell. Physiol."},{"key":"1467_CR437","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00281-017-0622-4","volume":"39","author":"N Bessis","year":"2017","unstructured":"Bessis, N., Decker, P., Assier, E., Semerano, L. & Boissier, M.-C. Arthritis models: usefulness and interpretation. Semin. Immunopathol. 39, 469\u2013486 (2017).","journal-title":"Semin. Immunopathol."},{"key":"1467_CR438","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/14712598.2017.1271873","volume":"17","author":"P Jayabalan","year":"2017","unstructured":"Jayabalan, P. & Schnitzer, T. J. Tanezumab in the treatment of chronic musculoskeletal conditions. Expert Opin. Biol. Ther. 17, 245\u2013254 (2017).","journal-title":"Expert Opin. Biol. Ther."},{"key":"1467_CR439","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrrheum.2017.164","volume":"13","author":"S Onuora","year":"2017","unstructured":"Onuora, S. Osteoarthritis: Wnt inhibitor shows potential as a DMOAD. Nat. Rev. Rheumatol. 13, 634 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1467_CR440","doi-asserted-by":"publisher","first-page":"638444","DOI":"10.3389\/fimmu.2021.638444","volume":"12","author":"X Lu","year":"2021","unstructured":"Lu, X., Hu, R., Peng, L., Liu, M. & Sun, Z. Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis. Front. Immunol. 12, 638444 (2021).","journal-title":"Front. Immunol."},{"key":"1467_CR441","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508\u2013519 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR442","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama, Z. T. & Scott, L. J. Baricitinib: a review in rheumatoid arthritis. Drugs 78, 761\u2013772 (2018).","journal-title":"Drugs"},{"key":"1467_CR443","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"Q Yao","year":"2023","unstructured":"Yao, Q. et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct. Target. Ther. 8, 1\u201331 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1467_CR444","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding, Q. et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct. Target. Ther. 8, 1\u201324 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1467_CR445","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","volume":"21","author":"F Berenbaum","year":"2013","unstructured":"Berenbaum, F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr. Cartil. 21, 16\u201321 (2013).","journal-title":"Osteoarthr. Cartil."},{"key":"1467_CR446","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jbmr.3388","volume":"33","author":"J Lu","year":"2018","unstructured":"Lu, J. et al. Positive-feedback regulation of subchondral H-type vessel formation by chondrocyte promotes osteoarthritis development in mice. J. Bone Miner. Res. 33, 909\u2013920 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"1467_CR447","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/annrheumdis-2020-218089","volume":"80","author":"W Hu","year":"2021","unstructured":"Hu, W., Chen, Y., Dou, C. & Dong, S. Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis. Ann. Rheum. Dis. 80, 413\u2013422 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1467_CR448","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bcp.2011.09.018","volume":"83","author":"S Casta\u00f1eda","year":"2012","unstructured":"Casta\u00f1eda, S., Roman-Blas, J. A., Largo, R. & Herrero-Beaumont, G. Subchondral bone as a key target for osteoarthritis treatment. Biochem. Pharmacol. 83, 315\u2013323 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"1467_CR449","doi-asserted-by":"publisher","first-page":"eaax3063","DOI":"10.1126\/scitranslmed.aax3063","volume":"12","author":"A-S Thorup","year":"2020","unstructured":"Thorup, A.-S. et al. ROR2 blockade as a therapy for osteoarthritis. Sci. Transl. Med. 12, eaax3063 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1467_CR450","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.arr.2017.12.006","volume":"42","author":"M Varela-Eirin","year":"2018","unstructured":"Varela-Eirin, M. et al. Cartilage regeneration and ageing: Targeting cellular plasticity in osteoarthritis. Ageing Res. Rev. 42, 56\u201371 (2018).","journal-title":"Ageing Res. Rev."},{"key":"1467_CR451","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1038\/s41591-022-02059-9","volume":"28","author":"N Gerwin","year":"2022","unstructured":"Gerwin, N. et al. Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. Nat. Med. 28, 2633\u20132645 (2022).","journal-title":"Nat. Med."},{"key":"1467_CR452","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1073\/pnas.1720658115","volume":"115","author":"P Occhetta","year":"2018","unstructured":"Occhetta, P. et al. Developmentally inspired programming of adult human mesenchymal stromal cells toward stable chondrogenesis. Proc. Natl Acad. Sci. USA 115, 4625\u20134630 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1467_CR453","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/oxfordjournals.jbchem.a022376","volume":"125","author":"T Fujisawa","year":"1999","unstructured":"Fujisawa, T. et al. Cyclic mechanical stress induces extracellular matrix degradation in cultured chondrocytes via gene expression of matrix metalloproteinases and interleukin-1. J. Biochem. 125, 966\u2013975 (1999).","journal-title":"J. Biochem."},{"key":"1467_CR454","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.joca.2020.01.003","volume":"28","author":"C Aulin","year":"2020","unstructured":"Aulin, C., Lassacher, T., Palmblad, K. & Erlandsson Harris, H. Early stage blockade of the alarmin HMGB1 reduces cartilage destruction in experimental OA. Osteoarthr. Cartil. 28, 698\u2013707 (2020).","journal-title":"Osteoarthr. Cartil."},{"key":"1467_CR455","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1302\/2046-3758.711.BJR-2018-0057.R1","volume":"7","author":"R-K Zhang","year":"2018","unstructured":"Zhang, R.-K. et al. Mechanical stress contributes to osteoarthritis development through the activation of transforming growth factor beta 1 (TGF-\u03b21). Bone Jt. Res. 7, 587\u2013594 (2018).","journal-title":"Bone Jt. Res."},{"key":"1467_CR456","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345\u20131352 (1999).","journal-title":"J. Clin. Invest."},{"key":"1467_CR457","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature04754","volume":"441","author":"PR Mangan","year":"2006","unstructured":"Mangan, P. R. et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231\u2013234 (2006).","journal-title":"Nature"},{"key":"1467_CR458","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1136\/annrheumdis-2015-207923","volume":"75","author":"Z Cui","year":"2016","unstructured":"Cui, Z. et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-\u03b2 activity and H-type vessel formation in subchondral bone. Ann. Rheum. Dis. 75, 1714\u20131721 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1467_CR459","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nm.3143","volume":"19","author":"G Zhen","year":"2013","unstructured":"Zhen, G. et al. Inhibition of TGF-\u03b2 signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med. 19, 704\u2013712 (2013).","journal-title":"Nat. Med."},{"key":"1467_CR460","doi-asserted-by":"publisher","first-page":"E6965","DOI":"10.3390\/ijms21186965","volume":"21","author":"T Carvalheiro","year":"2020","unstructured":"Carvalheiro, T. et al. Semaphorin4A-plexin D1 axis induces Th2 and Th17 while represses Th1 skewing in an autocrine manner. Int. J. Mol. Sci. 21, E6965 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1467_CR461","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3389\/fimmu.2020.02151","volume":"11","author":"J Xie","year":"2020","unstructured":"Xie, J., Wang, Z. & Wang, W. Semaphorin 4D induces an imbalance of Th17\/Treg cells by activating the aryl hydrocarbon receptor in ankylosing spondylitis. Front. Immunol. 11, 2151 (2020).","journal-title":"Front. Immunol."},{"key":"1467_CR462","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/art.41701","volume":"73","author":"J Avouac","year":"2021","unstructured":"Avouac, J. et al. Semaphorins: from angiogenesis to inflammation in rheumatoid arthritis. Arthritis Rheumatol. 73, 1579\u20131588 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1467_CR463","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13075-021-02622-8","volume":"23","author":"D McGuire","year":"2021","unstructured":"McGuire, D. et al. Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA. Arthritis Res. Ther. 23, 242 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1467_CR464","doi-asserted-by":"crossref","unstructured":"Zhu, S. et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J. Clin. Invest. 129, 1076\u20131093 (2019).","DOI":"10.1172\/JCI121561"},{"key":"1467_CR465","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","volume":"7","author":"JN Tsai","year":"2019","unstructured":"Tsai, J. N., Lee, H., David, N. L., Eastell, R. & Leder, B. Z. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 7, 767\u2013775 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1467_CR466","doi-asserted-by":"publisher","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","volume":"139","author":"B Langdahl","year":"2020","unstructured":"Langdahl, B. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 139, 115516 (2020).","journal-title":"Bone"},{"key":"1467_CR467","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. Publ. Protein Soc. 30, 70\u201382 (2021).","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"1467_CR468","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1172\/JCI28775","volume":"116","author":"D Mao","year":"2006","unstructured":"Mao, D., Epple, H., Uthgenannt, B., Novack, D. V. & Faccio, R. PLC\u03b32 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest. 116, 2869\u20132879 (2006).","journal-title":"J. Clin. Invest."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01467-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T05:15:58Z","timestamp":1702444558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":468,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01467-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"1 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}